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1. Summary 
Background: The gene Coiled Coil Domain Containing 80 (Ccdc80) is widely expressed in 
normal human tissues, at particularly high levels in heart, skeletal muscle and adipose tissue. 
Its role is well defined in tumor suppression, axon path finding, glucose homeostasis, bone 
marrow stromal cells and adipocyte differentiation. Moreover, it plays a role in embryonic 
development of lens and muscle, but no clear-cut data are available about the role of Ccdc80 
in heart development and in heart disease.   
Aims: To define if Ccdc80 is expressed during embryonic development of zebrafish heart and 
if its functional block causes alterations of heart structure or contractility; to define the 
expression pattern of Ccdc80 protein in normal heart vs cardiomyopathies in humans 
(samples taken from patients with dilated cardiomyopathy – DCM) and rodents (samples 
taken from right ventricle heart failure induced by monocrotaline – MCT). 
Results: In zebrafish Ccdc80 is widely expressed in the forming heart, during all the 
developmental stages; Ccdc80-morphants show defects in the developing heart, with impaired 
cardiac looping, atrium enlargement, blood stasis and peripheral congestion. These 
phenotypical alterations, similar to  heart failure, are due to a disorder of the late phase of 
cardiac development, after myocyte differentiation.  
In normal human and rats, Ccdc80 mRNA, analized by Northern blot technique,  showed a 
higher expression in atria compared to ventricles, while the Ccdc80 protein (108 Kd), analized 
by Western blot, showed similar expression levels in atria and ventricles. Ccdc80 protein 
showed different expression patterns, in atria and ventricles with a cytoplasmic localization 
and co-localization with sarcomeric proteins at immunofluorescence analysis. 
 In pathological samples (DCM and MCT rats) Ccd80 protein showed evident overexpression 
and different isoforms, related to protein phosphorylation and secreted protein isoform, suggesting 
a different feature in pathological conditions compared to normal. 
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Conclusions: Our results demonstrated that Ccdc80 has an indispensable role for correct heart 
development. In complete developed heart, Ccdc80 showed an adaptive function to stress 
conditions, such as pressure overload, and in cardiomyopathies showed increased expression 
and different isoforms. 
 
2. Riassunto 
Introduzione: Il gene Coiled Coil Domain Containing 80 (Ccdc80) è ampiamente espresso in 
tessuti umani normali, a livelli particolarmente elevati nel cuore, muscolo scheletrico e tessuto 
adiposo. E’ ben definito il suo ruolo come oncosoppressore, nella innervazione degli assoni, 
nella omeostasi glicemica, e nel differenziamento delle cellule stromali del midollo osseo e 
degli adipociti. Inoltre, svolge un ruolo nello sviluppo embrionale muscolare e della lente del 
cristallino, ma non sono disponibili dati sul ruolo di Ccdc80 nello sviluppo del cuore e nelle 
malattie cardiache. 
Obiettivi : Definire se Ccdc80 è espresso durante lo sviluppo embrionale del cuore zebrafish 
e se il suo blocco funzionale provoca alterazioni della struttura o della contrattilità; definire il 
pattern di espressione della proteina Ccdc80 nel cuore normale vs cardiomiopatie nell'uomo 
(campioni prelevati da pazienti con cardiomiopatia dilatativa - DCM ) e roditori (campioni 
prelevati da ratti con insufficienza ventricolare destra indotta da monocrotalina - MCT). 
Risultati: In zebrafish Ccdc80 è ampiamente espresso nel cuore in formazione, durante tutte 
le fasi di sviluppo; i morfanti per Ccdc80 mostrano difetti nello sviluppo cardiaco, con 
alterato looping, dilatazione atriale, stasi ematica e congestione periferica. Queste alterazioni 
fenotipiche, simili ad uno scompenso cardiaco, sono dovuti ad un disturbo della fase tardiva 
dello sviluppo cardiaco, dopo che la differenziazione dei miociti è già stata completata. 
Nei campioni normali di uomo e ratto, l’RNA messaggero di Ccdc80, analizzato con tecnica 
di Northern blot, è risultato maggiormente espresso negli atri rispetto ai ventricoli, il mentre 
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l’espressione della proteina Ccdc80 (108 Kd), analizzata con tecnica Western blot, è risultata 
simile negli atri e nei ventricoli.  La proteina Ccdc80 ha mostrato pattern  di espressione 
diversi in atri e ventricoli, con localizzazione citoplasmatica e chiara co-localizzazione con le 
proteine sarcomeriche all’immunofluorescenza. Nei campioni patologici (DCM ed MCT ratti) 
la proteina Ccd80 ha mostrato  una netta iper-espressione sia negli atri che nei ventricoli, e la 
presenza di diverse isoforme, suggerendo diverse funzioni in condizioni patologiche rispetto 
al normale . 
Conclusioni: I nostri risultati hanno dimostrato che Ccdc80 ha un ruolo indispensabile nello 
sviluppo cardiaco. Nel cuore adulto, Ccdc80 si manifesta con diverse isoforme e maggiore 
espressione, rivestendo una funzione adattativa in condizioni di stress, come il sovraccarico di 
pressione, e nelle  cardiomiopatie. 
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3. Aim of the study 
Aims of our investigation are:  
1. Define the functional role of Ccdc80 in embryonic development of zebrafish heart, in 
particular evaluate if the gene is expressed during heart formation and if its functional block 
causes alterations of heart structure or contractility; 
2. Define the expression pattern of Ccdc80 protein in normal heart and muscle of rodents and 
humans; 
3. Define the expression pattern of Ccdc80 protein in cardiomyopathies both in rodents and 
humans.  
 
4. Introduction  
4.1 Cardiomyopathies, definition and classification 
Cardiomyopathies are a broad spectrum of diseases that affect the muscle or myocardium of 
the heart. The official definition of cardiomyopathy by the American Heart Association 
(AHA) in 2006 is as: “Cardiomyopathies are a heterogeneous group of diseases of the 
myocardium associated with mechanical and/or electrical dysfunction that usually (but not 
invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety 
of causes that frequently are genetic. Cardiomyopathies either are confined to the heart or are 
part of generalized systemic disorders, which may lead to cardiovascular death or progressive 
heart failure-related disability [1].” Otherwise, the working group of the European Society of 
Cardiology (ESC) in 2008 defined cardiomyopathy as: “A myocardial disorder in which the 
heart muscle is structurally and functionally abnormal, in the absence of coronary artery 
disease, hypertension, valvular disease and congenital heart disease sufficient to cause the 
observed myocardial abnormality [2].” A complete classification based on the above AHA 
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definition divides cardiomyopathies into (1) primary cardiomyopathies, which affect the heart 
alone, and (2) secondary cardiomyopathies, which are the result of a systemic illness affecting 
many other parts of the body. These are then further broken down into subgroups within these 
two broad categories incorporating new genetic and molecular insights (Figure 1). 
Historically, most cardiomyopathies have been defined by the absence of particular features 
or associated disorders, but it is increasingly apparent that many patients with unexplained 
heart muscle disease in fact have rare, but well described diseases that can involve the 
myocardium. 
 
Figure 1 
Summary of AHA 2006 and ESC 2008 Classification. DCM: dilated cardiomyopathy; HCM: hypertrophic 
cardiomyopathy; ARVC: arrhythmogenic right ventricular cardiomyopathy;  
RCM: restrictive cardiomyopathy. 
 
4.2 Dilated cardiomyopathy and heart failure 
Dilated Cardiomyopathy (DCM) is a common cause of congestive cardiac failure and is 
defined by the presence of left ventricular dilatation and systolic dysfunction in absence of 
coronary artery disease or other causes such as hypertension or valvular pathology [2]. The 
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right ventricle may be involved but is not necessary for the diagnosis. The exact prevalence of 
DCM  in the general population is unknown, but it clearly varies with age and geography; [3] 
DCM has an incidence of more than 36.5 cases per 100,000 persons and it accounts for nearly 
50,000 hospitalizations and 10,000 deaths each year in the United States. For now, dilated 
cardiomyopathy remains the primary indication for heart transplantation in the Western 
countries [4]. As aforementioned, DCM is one of the most common cause of Heart Failure 
(HF), as well as ischemic heart disease, valvular heart disease, viral myocarditis. The onset 
and progression of HF is closely associated with several molecular and cellular alterations [5], 
including abnormal calcium handling, neurohumoral activation, increased oxidative stress, 
and abnormal cytokine signalling. The left ventricle dysfunction and low cardiac output lead 
to compensatory activation of the sympathetic nervous system and the renin–angiotensin and 
vasopressin system. However, these compensatory mechanisms throughout years can worst 
the cardiac dysfunction and exacerbate the pathophysiology of HF. This is the major reason 
that medications for HF include angiotensin-converting enzyme inhibitors and β-blockers.  
Drug treatment has advanced markedly over the past 20 years and the employ of cardiac 
implantable defibrillators and electric resynchronization therapy has improved the prognosis 
of patients with HF. However, despite an optimal cardiovascular treatment, chronic HF is still 
a progressive disorder with high morbidity and mortality, suggesting that important 
pathogenic mechanisms remain unmodified by the present treatment modalities as immune 
activation and persistent inflammation. 
Beside humoral and cell-mediated immune responses, familial forms have been implicated in 
idiopathic dilated cardiomyopathy. 
Indeed, around 30–50% of cases have a familial component [6], and more than 30 genes have 
been identified, to date, that cause DCM. Most are inherited in an autosomal dominant 
fashion although some can be autosomal recessive, X-linked or mitochondrial. The actual 
frequency of familial DCM is probably underestimated.  
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Peripartum cardiomyopathy is a specific subgroup of dilated cardiomyopathy defined as the 
development of heart failure with evidence of left ventricular dysfunction, within the last 
month of pregnancy to within 5 months of delivery, without other identifiable cause or 
underlying cardiac condition [7, 8]. Groups of women presenting during the earlier stages of 
pregnancy have been identified and with similar epidemiological characteristics and with 
similar disease progression and outcomes. The earlier time frame of presentation has been 
postulated to represent part of a spectrum of peripartum cardiomyopathy [9]. 
Peripartum cardiomyopathy affects approximately 1 : 4000 women across the US and Europe 
each year, with higher rates noted across the African continent [10]. The aetiology of 
peripartum cardiomyopathy has been unclear for many years; however, new research into an 
inflammatory or immunological basis, and the role of prolactin in the development of the 
disease has shed new light on the causative mechanisms that may be behind this condition. 
Familial clustering of peripartum cardiomyopathy has been identified; however, on screening 
other family members and with further genetic testing, this clustering may represent a subset 
of undiagnosed familial dilated cardiomyopathy. TNF alpha, and other proinflammatory 
cytokines have been shown to be elevated in a large number of peripartum cardiomyopathy 
cases and similarly some studies have suggested a role for autoantibodies against normal 
human cardiac tissues proteins and further research is required in this area [11]. Higher levels 
of CRP, Fas/Apo-1, TNF alpha and IL-6 have been demonstrated in some population groups 
with peripartum cardiomyopathy and have implicated a role for inflammatory mediator in the 
disease process [12, 13]. 
Mutations in relevant genes can cause DCM. [14-20] (Figure 2). It is estimated that 
myofibrillar protein mutations account for roughly 10% of familial DCM cases [21] but a 
recent finding suggests that 25% of idiopathic DCM cases are due to sarcomeric gene 
mutations [22]. Sarcomere proteins include heavy and light chain myosin and myosin binding 
proteins, cardiac actin, α-tropomyosin, troponin complexes, and others. Common sarcomere 
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gene mutations identified in DCM as a cause of familial and sporadic disease include β-
myosin heavy chain (MYH7) missense mutations. Other disease-causal gene mutations 
include Troponin T (TNNT2) missense or deletion mutations; Troponin C (TNNC1) missense 
mutations [23-25]; Troponin I (TNNI3) missense mutations [26, 27]; α-tropomyosin (TPM1) 
missense mutations [28-30]; and cardiac actin (ACTC) missense mutations [31]. Concerning 
mutations, the MYH7 gene is the most frequently mutated in the familial DCM population 
(approximately 10% of cases), although disease onset is delayed, with incomplete disease 
penetrance, compared with that for mutations of TNNT2 and TNNC1 genes. In addition to 
gene mutations that affect sarcomeric proteins, gene mutations of structural proteins such as 
the intermediate filament proteins and the dystrophin-associated glycoprotein complex are 
known as a cause of DCM. Intermediate filaments are important components of the 
cytoskeletal system that stabilize organelles by linking the Z-disc to the sarcolemma. Desmin 
(des) is a component of type III intermediate filaments, and missense mutation can cause 
DCM [32]. In addition, many missense and deletion mutations have been shown to cause 
myofibrillar myopathy (MFM; also called desmin-related myopathy) [33-34]. The MFM 
caused by desmin gene mutations, such as a putative 7-amino acid deletion and missense 
mutations, are heterogeneous myopathies characterized by abnormal intrasarcoplasmic 
desmin accumulation. Concerning sarcomere stability and force transmission to the 
extracellular matrix, the importance of protein interactions among dystrophin (DMD), actin 
(ACTC1), and the dystrophin-associated glycoprotein complex composed of α- and β-
dystroglycans (DAG1), γ- and δ-sarcoglycans (SGCG and SGCD), caveolin-3 (CAV3), and 
dystrobrevin (DTNA) is well recognized [35-36]. Muscular dystrophy with associated DC M 
and heart failure is caused by many kinds of dystrophin mutation, such as deletion of the first 
muscle exon and the muscle-promoter region of the DMD gene, a splice donor site mutation 
in the first exon, or mutations in intron regions of the DMD gene that inactivate the 
universally conserved 5-prime splice site consensus sequence of the first intron [37-38]. 
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Mutation of a dystrophin-associated protein, such as an S151A substitution in the SGCD 
gene, can also cause familial and sporadic dilated cardiomyopathy [39] Calcium regulating 
proteins and disturbed ion channel function have been identified as causative of DCM [40-
41]. Phospholamban (PLN) is known as a regulator of calcium uptake into the sarcoplasmic 
reticulum (SR) via inhibition of SR Ca2+-ATPase (SERCA2) in cardiomyocytes. The PLN 
R9C mutation and arginine 14 deletion mutation (R14Del) in PLN lead to disease through 
cardiomyocyte calcium dysregulation. It is thought that PLN R9C protein can trap protein 
kinase A, which blocks PKA-mediated phosphorylation of wild-type PLN, and PLN R14Del 
protein can inhibit SR ATPase, despite phosphorylation by protein kinase A. 
 
Figure 2 
Summary of Causal Genes of Dilated Cardiomyopathy (DCM) 
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4.3 Other cardiomyopathies 
Hypertrophic cardiomyopathy (HCM) has been defined by the presence of myocardial  
hypertrophy incongruent with the haemodynamic stress required for the degree of 
hypertrophy and the exclusion of infiltrative diseases such as amyloidosis and 
storage diseases [42-43]. In the absence of hypertension and valve disease, left ventricular 
hypertrophy (LVH) occurs in approximately 1 : 500 of the general population [44]. In day-to-
day clinical practice it is very difficult to differentiate between pathologies using minimally 
invasive techniques such as cardiac echo or cardiac magnetic resonance imaging (MRI). 
Histological demonstration (on myocardial biopsy) of myocyte hypertrophy in the definition 
of HCM is unreliable due to the patchy nature of the abnormality within the myocardium. The 
position statement from the ESC [2] contained the following “the presence of intramyocardial 
storage material is not an exclusion criterion for HCM. Instead, hypertrophic 
cardiomyopathies are simply defined by the presence of increased ventricular wall thickness 
or mass in the absence of loading conditions (hypertension, valve disease) sufficient to cause 
the observed abnormality.” The potential inaccuracy in not fully excluding infiltrative disease 
or demonstrating myocyte hypertrophy on biopsy is justified by leading to increased emphasis 
in the clinical picture and a promise of better minimally invasive diagnostic strategies. If the 
HCM is familial, then it is usually transmitted in an autosomal dominant pattern of 
inheritance caused by mutations within genes that encode for various proteins of the cardiac 
sarcomere (Figure 3). Currently, there are over 500 mutations in 13 genes that have been 
identified that cause HCM and 50% of these are familial [45-48]. Pathologically, left 
ventricular (LV) cavity size is normally reduced and this can progress to LV dilatation and 
heart failure, albeit in a minority of patients. There are many patterns of hypertrophy and all 
are consistent with a diagnosis of HCM but concentric hypertrophy is more suggestive of a 
systemic cause such as glycogen storage disease. Moreover, mutations in the genes encoding 
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for cardiac troponins can be associated with mild phenotypes but, conversely, a high 
incidence of cardiac death [49]. 
 
Figure 3 
Genes associated with hypertrophic cardiomyopathy. 
 
Restrictive cardiomyopathies have a diverse range of aetiology; however, all are recognised as 
having distinct haemodynamic features separating them from other forms of cardiomyopathy. 
Restrictive cardiomyopathies in general are defined as showing normal ventricular size 
(nondilated and non-hypertrophied) with impaired haemodynamic function, elevated filling 
pressures, and diastolic dysfunction, and in most cases normal systolic function [50-51]. 
Presentation can include symptoms of both right and left sided failure; decreased exercise 
tolerance, dyspnoea, peripheral oedema, and palpitations are the most common 
symptoms. Due to the contrast in both aetiology and treatment options and the similarities in 
haemodynamics, it is important to recognise the difference between restrictive 
cardiomyopathy and constrictive pericarditis. Usually, this is defined with a variety of 
investigatory modalities with both haemodynamic and morphological assessment and 
includes echocardiography and pericardial imaging [52]. Various aetiologies have been 
identified as causing restrictive cardiomyopathy and range from idiopathic (primary) 
restrictive cardiomyopathy, to systemic conditions including infiltrative, noninfiltrative, and 
storage disorders, as well as endomyocardial disorders, various medications, and iatrogenic 
causes [53]. Familial restrictive cardiomyopathies are usually inherited in an autosomal 
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dominant fashion, the genetic basis of which remains to be identified, and are noted to be 
relatively rare [54]. Hereditary conditions known to cause a restrictive cardiomyopathy 
include haemochromatosis, glycogen storage diseases, Fabry’s disease, Gaucher’s disease, 
and Hurler syndrome. 
Arrhythmogenic Right Ventricular Dysplasia (ARVD) is a heart muscle disease which, 
pathologically, consists of progressive fibrofatty replacement of the right ventricular 
musculature which may or may not involve the left ventricle. It predisposes towards 
malignant arrhythmias originating from the right ventricle and is a major cause of sudden 
death in young athletes [55]. Major and minor criteria of ARVD diagnosis have been 
compiled, and the diagnosis can be made if there are two major, one major and one minor or 
four minor criteria present [56]. Diagnosis and risk stratification are extremely important as 
there are proven life saving interventions which are available to the clinician [57]. 
It is a familial disease in around 50% of cases and is usually transmitted in an autosomal 
dominant fashion [58]. The first gene, ARVD1, coding for a desmosome protein, was 
discovered in 1994 [59], and since then multiple causative genes relating to the desmosome 
have been discovered, indicating that ARVD is a disease of the desmosome (Figure 4) [60-
66]. 
 
Figure 4 
Genes associated with ARVD 
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4.4 Ccdc80 gene/protein 
 
Ccdc80 (also known as CL2, DRO1, equarin, SSG1, and URB) was initially identified as an 
estrogen-induced gene in rat uterus and mammary gland [67] and in a rat model of thyroid 
carcinogenesis. Chicken [68], mouse [69], and human [70] orthologs have also been 
identified, but little is known about the function of Ccdc80. Ccdc80 mRNA has been found to 
be up-regulated in brown adipose tissue from old but not young bombesin receptor subtype-3 
(BRS-3)-deficient mice. Moreover, Ccdc80 was found to be strongly upregulated in PC CL3 
epithelial thyroid cells immortalized by the adenovirus E1A gene (PC E1A cells) [71-72] 
(Figure 5). 
                                             
Figure 5 
Analysis of the expression of the Ccdc80 gene in PC Cl 3, PC E1A and PC HE4 cells  
10 micro-g of total RNA for each cell line was size-fractionated on a 1.2% denaturing formaldehyde agarose gel, 
blotted onto Nylon filters hybond-N and probed with a 1.1 kb EcoRI/HindIII fragment from the pGem3ZCcdc80 
vector, b-actin was used as control for uniform RNA loading [71]. 
 
Ccdc80 cDNA analysis showed a single long Open Reading Frame (ORF), which has the 
potential to code for a 949 amino-acid protein, having a molecular mass of 107.7 kDa [71] 
(Figure 6). 
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Figure 6  
In vitro transcription–translation of the rat Ccdc80 protein  
In vitro transcription–translation was performed in the presence of [35S]methionine using the TNT Promega kit. 
A total of 3 µl of the reaction was loaded on a 10% SDS–PAGE and autoradiographed. As expected, the 
translation product migrates around 107 kDa. The construct pcDNA3-RET/PTC3 (lane +), encoding an unrelated 
protein of about 70 kDa, was used as positive control for the transcription–translation reaction [71].  
 
The highly basic (pI 9.6) protein has multiple potential nuclear localization signals at amino-
acid positions 420, 545, 549, 569, 573 and 583. Furthermore, it has a potential signal peptide 
(SP) ending at amino-acid 24. Taken together, these results suggest that the Ccdc80 gene 
encodes either nuclear or secreted proteins. This was confirmed by an in vitro experiment, in 
which COS7 cells were transfected with an expression vector containing the entire ORF of 
Ccdc80 fused in-frame with the EGFP (Enhanced Green Fluorescent Protein) gene. 
Expression of EGFP-Ccdc80 resulted in two different sub-cellular localization patterns: in 
most cells the fluorescent signal was juxtanuclear, indicating a Golgian localization, while in 
the 5-10% of them it was nucleo-cytoplasmic (Figure 7). 
          
Figure 7  
Cellular localization of EGFP-Ccdc80 in COS7 cells  
COS7 cells were transiently transfected and monitored for EGFP-Ccdc80 expression 48 h post-transfection. 
Fluorescence was examined with a Zeiss LSM410 scanning confocal microscope. Panel (a) COS7 cells 
transfected with the EGFP control vector. Panel (b) Polar perinuclear accumulation of the EGFP-Ccdc80 signal, 
suggestive of a Golgian localization. Panel (c) The signal is spread throughout the cytoplasm, with some 
nuclear–nucleolar staining, heterogeneous in intensity depending on the cell [71]. 
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Searching for common motifs in the Ccdc80-encoded protein, a cluster of subsequences was 
identified, which occur three times along the protein and identify three domains (D1, D2, D3), 
which show an overall identity of 27% and a similarity of 48% (Figure 8). The BLAST 
screening with the Ccdc80 domains as probes identified three proteins sharing 27% identity 
and 46% similarity with them. These proteins are encoded by the rat drs (down-regulated by 
v-src) gene [73], its human homologue ETX1 (or SRPX, sushi-repeat containing protein 
chromosome X) gene [74], and the human SRPUL (sushi-repeat protein up-regulated in 
leukemia) gene [75].  
 
                        
Figure 8  
Schematic representation of mouse Ccdc80 protein 
 
Screening of human sequences in the GenBank database with the rat Ccdc80 cDNA revealed 
a sequence containing the complete ORF of the human Ccdc80 gene, which is located 
between chromosomal bands 3q 13.2-3q 13.3 and in a tel-5’-3’-cen orientation. The predicted 
human Ccdc80 amino acid sequence was highly conserved (82% identity and 86% similarity) 
with respect to that of the rat, indicating an important role of Ccdc80 in higher eukaryotes. 
Northern blot analysis of poli(A)
+ 
mRNA from adult human tissues showed that Ccdc80 is 
almost ubiquitously expressed in two alternative forms of the transcript, 4.2 and 3.8 kb, 
suggesting its role in the functioning of many organs. The highest expression was observed in 
heart, the lowest in brain, liver, spinal cord, and lymph node, while it was not detectable in 
bone marrow and peripheral blood leucocytes (Figure 9).  
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Figure 9 
Expression pattern of Ccdc80 mRNA in human tissues 
Human multiple tissue Northern blot was hybridized with a 1.1 kb EcoRV/HindIII fragment from the 
pGem3ZCcdc80 vector. Autoradiograms were exposed for 4 days [71]. 
 
During mouse embryonic development, northern blot results showed Ccdc80/URB expression 
starting from the lowest level at 7 days post coitum (dpc) up to the highest level at 17 dpc 
[71]. Liu et al. [76], described an abundant expression in rib, sternal cartilage, heart, kidney, 
and leg muscles in both embryos and newborn mice. Moreover, the authors performed an ISH 
analysis on developing embryos, detecting evident expression of the URB transcript in the 
developing cartilage of the developing skeleton until 14 dpc, and a bare expression in a 
ventricular zone of the central nervous system. In the same work, an immunohistochemical 
analysis at 17 dpc revealed the presence of the URB protein in the extracellular matrix of 
hypertrophyc chondrocytes. This suggests for URB a role during embryogenesis, in particular 
in the development of skeleton. Liu et al., further investigated the expression of URB gene in 
human differentiating bone marrow stromal cells (BMSC), which are a heterogeneous stem-
cell-like population residing in the bone marrow cavity, which can differentiate in multiple 
mesenchymal lineages, such as chondrocytes, osteoblasts, and adipocytes. In this case, URB 
expression was strongly downregulated during in vitro osteoblastic differentiation.  
Three human proteins, SRPX, SRPX2 and Ccdc80, possess a conserved region of similarity 
with repeated domains, and are all involved in tumor suppression and progression. Bommer et 
al. named these repeated regions as DUDES (DRO1-URB-DRS-Equarin-SRPUL) [70], but 
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were identified many prokaryotic homologs: so was decided to rename the domain to P-
DUDES (Prokaryotes-DUDES) [77]. 
The vertebrate P-DUDES proteins are multidomain, possessing one (SRPX and SRPX2) or 
three (Ccdc80) P-DUDES domains (Figure 10). The similarity of the C-terminal regions of 
SRPX and SRPX2 proteins, referred to herein as P-DUDES domain, to the three repeat 
regions in Ccdc80 was noticed early [67, 68]. The three genes appear to be conserved in all 
vertebrates for which full genome information is available, although in fishes (e.g. Danio 
rerio, Tetraodon nigroviridis) there are three distinct paralogues of the Ccdc80 gene.  
                       
Figure 10 
Diagram showing domain composition of representative P-DUDES proteins 
 
The similarities of vertebrate P-DUDES domains suggest that the common ancestor of 
vertebrates had a duplicated SRPX-like gene and that the common ancestor of vertebrates had 
at least one Ccdc80-like gene. P-DUDES domains appear to be absent from nonvertebrate 
chordates, and all other metazoans. The sequence similarity of P-DUDES to peroxiredoxins 
and to bacterial comigratory proteins, in particular, may reflect only the general fold similarity 
because the cysteine residue, important for peroxiredoxin function, is not conserved in the P-
DUDES domain. 
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4.5 Ccdc80 and morphogenesis 
Another ortholog of the Ccdc80 gene, named Equarin [68], was found to be involved in the 
morphogenesis of the chicken lens (Figure 11). Two splicing variants (4.2 kb Equarin-L and 
3.9 kb Equarin-S) of the gene were identified and they were demonstrated to be expressed in 
the isthmus, in the 4
th 
and 6
th 
rhombomers, and in the anterior pore of the neural tube beside 
the lens. 
The ectopic injection of the transcripts in Xenopus embryos was found to impair normal 
retinal development. This evidence reveals that Equarin has a broader role during eye 
development. The same study also confirmed, by immunoblotting analysis, the secreted 
nature of the encoded protein, which is modified, cleaved, and secreted after translation.  
 
                                
Figure  11 
Localization of equarin-S and equarin-L mRNAs during early lens development 
(a) Equarin-S is first detected in the lens placode at stage 14 (arrowheads in a and b). (b) Dorsal view of 
(a). (c) Equarin-L is first detected in the lens vesicle at stage 17 (arrowhead). (d) Coronal section of the 
eye at stage 17 (proximal is downwards, dorsal towards the right). Note that equarin-L is localized on 
the proximal side of the lens vesicle. (e) Lateral view of stage 19 embryo. The distributions of equarin-S 
and equarin-L transcripts are identical. Note that equarin transcripts are strongly expressed in the lens 
(white arrowhead) with a high-dorsal-to-low-ventral gradient (e,f). Equarin transcripts are also 
expressed in the isthmus (arrowhead), the rhombomeres (particularly strongly at r4 and r6; open 
arrowhead), and the anterior pore of the neural tube (arrow). (f) High magnification of the eye shown in 
(e). (g) Coronal section of the eye in (e) with the same orientation as (d). Scale bars: 50 mm [68]. 
 
In another study [78], the zebrafish homologues Ccdc80 and Ccdc80-like1 proteins (Ccdc80-
l1) are showed to be expressed in nervous and non-nervous tissues, in particular in territories 
correlated with axonal migration. Loss of Ccdc80 impaired somitogenesis and loss of 
Ccdc80-l1 in zebrafish embryos induced motility issues suggesting that Ccdc80-l1 is involved 
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in axon guidance of primary and secondary motoneurons populations. In particular, Ccdc80-l1 
has a differential role as regards the development of ventral and dorsal motoneurons, and the 
axonal migration defects are similar to the phenotype of several mutants with altered 
Hedgehog activity. Indeed, was reported that Ccdc80-l1 expression is positively regulated by 
the Hedgehog pathway in adaxial cells and muscle pioneers [79]. These findings strongly 
indicate Ccdc80-l1 as a down-stream effector of the Hedgehog pathway. 
 
4.6 Ccdc80 and tumors 
In recent years, more reports on P-DUDES proteins appeared, bringing the attention to 
differential expression of SRPX, SRPX2, and Ccdc80 genes in various developmental 
processes and in various tumors. In general, SRPX2 was reported as overexpressed in cancer 
while SRPX and Ccdc80 were identified as downregulated in malignant conditions [70]. The 
two latter genes were described as tumor suppressors, and some relevant tumor suppression 
mechanisms were proposed. The P-DUDES gene with links to cancer most broadly 
documented is SRPX. It was found to be downregulated in malignant pulmonary 
neuroendocrine tumors [80] whereas its downregulation was correlated with the malignancy 
of the tumor (most downregulation observed in tumors is related to shortest survival time). Of 
note, 30% of SRPX knock-out mice developed various tumors: lymphoma, lung cancer, 
hepatoma, sarcoma [81], while no tumors appeared in the control wild-type mice. The 
proposed mechanism of tumor suppression by SRPX is induction of apoptosis. Ectopic 
expression of the SRPX protein induced apoptosis in human cancer cell lines. Both the P-
DUDES and the sushi repeat regions were necessary for apoptosis induction, and SRPX 
activated caspases-12, -9, and caspase-3 [82]. Reintroduction of SRPX into lung cancer cell 
line from SRPX knock-out mice led to the suppression of tumor formation, accompanied by 
enhanced apoptosis [81]. 
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SRPX-mediated apoptosis was correlated with the suppression of tumor formation [81]. 
However, the tumor suppression mechanism mediated by SRPX is more complicated than 
solely that of apoptosis induction serum, as studied in SRPX knock-out mouse-derived 
fibroblast cultures [83]. Thus, P-DUDES, since a recent report shows that this gene is 
involved in the maturation process of autophagy induced by low proteins may mediate both 
apoptosis and autophagy which suggests for its broader function. In a manner somewhat 
reminiscent of SRPX, Ccdc80 was found to suppress anchorage independent growth and 
sensitize cells to anoikis and CD95-induced apoptosis. Interestingly, Ccdc80 protein is 
localised to endothelial cells of the vasculature of the tumors [67] which may suggest a role in 
angiogenesis for Ccdc80. Of implication to a role in cancer is the observation that mouse 
Ccdc80 is involved in assembly of extracellular matrix and mediates cell adhesiveness [84]. 
Confirming its possible role in regulation of tumor growth, a RT-PCR analysis showed that 
Ccdc80 expression was clearly detectable in normal human thyroid tissue while strongly 
down-regulated or absent in both human thyroid carcinoma cell lines and tumors [71].  
Moreover, Bommer et al. [70] demonstrated that DRO1 (down-regulated by oncogene 1, the 
way they named human Ccdc80) gene is extremely downregulated in colon and pancreatic 
cancer cell lines, as well as in most colorectal cancer specimens with respect to the 
corresponding non tumor cell lines and tissues. Similar evidence have been obtained on liver 
specimens from patients affected by hepatocellular carcinoma (HCC), which showed a down-
regulation of the gene in 80% of HCCs when compared to their surrounding cirrhotic tissue. 
Furthermore, human Ccdc80 ectopic expression in tumor cell lines, lacking endogenous 
Ccdc80 expression, impaired their growth capabilities, making cancer cells susceptible to 
apoptotic stimuli [70]. 
Another study [85] confirms the Ccdc80 down-regulation in thyroid carcinomas, supporting 
the concept that CL2/Ccdc80 plays a role in human thyroid carcinogenesis by mediating the 
control of cell growth, invasion, and apoptosis. The reduction of CL2/Ccdc80mRNA was 
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greatest in the follicular variant with an average down-regulation of~51.3-fold. Interestingly, 
the CL2/ Ccdc80 protein was delocalized from the nucleus to the cytoplasm in those 
carcinoma samples that retained detectable levels of the protein, also shuttling from Golgi to 
the endoplasmic reticulum to exert its apoptotic function. Furthermore, the results of 
experiments on restoration of CL2/Ccdc80 gene expression in thyroid carcinoma cell lines 
indicate that loss of this gene expression plays a critical role in thyroid carcinogenesis. In fact, 
the growth rate of cells transfected with a CL2/Ccdc80 expression vector was significantly 
reduced. Moreover, flow cytometric analysis, confirmed by the TUNEL assay, showed a shift 
of the DNA profile of CL2/Ccdc80 transfected cells to a subG1 position, which is consistent 
with the concept that CL2/Ccdc80 expression exerts an apoptotic effect. This finding is also 
in line with the recent finding that CL2/Ccdc80 plays a crucial role in the apoptotic process 
[86]. Finally, the oncosuppressor function of the CL2/Ccdc80 gene was clearly indicated by 
the suppression of the neoplastic phenotype by the cells reexpressing CL2/Ccdc80. Indeed, 
these cells were no longer able to efficiently grow in semisolid medium and did not induce 
tumors when injected into athymic mice. 
Ccdc80 is also repressed in AIB1 transgenic mice [86]. AIB1 is an oncogene that functions as 
a transcriptional coactivator in the nucleus [87-88]. Nuclear shuttling of AIB1 correlates with 
cell cycle progression in non-cancer cells [89], but this distribution is altered in cancer cell 
lines [88]. AIB1 overexpression occurs in many types of tumors and this is also the cause of 
cancer in animal models. In agreement, AIB1 represses DRO1 promoter and its expression 
levels inversely correlate with DRO1 in several cancer cell lines and in ectopic and silencing 
assays. Importantly, DRO1 shuttles from Golgi to the endoplasmic reticulum upon apoptotic 
stimuli, where it is predicted to facilitate the apoptosis cascade and  DRO1 overexpression 
resulted in BCLAF1 upregulation. Therefore, DRO1 repression is an important factor for 
AIB1-mediated inhibition of apoptosis.  
All these observations suggest that Ccdc80 may have a role as a tumor suppressor gene.  
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Figure  12 
Comparison of Ccdc80-RNA expression in healthy controls  and in patients with colorectal cancer,  
from NCBI GEO database 
 
 
4.7 Ccdc80 and metabolic regulation 
The function of both the human and mouse orthologs of Ccdc80 was also investigated in 
adipose tissues. Here the gene was named URB (upregolated in bombesin receptor subtype 3 
knockout mouse) [69] and was demonstrated to be down-regulated in obese mice [90]. Was 
actually demonstrated that URB mRNA was predominantly expressed in human and mouse 
adipose tissues and was downregulated in obese mice; mRNA expression of URB in 3T3L1 
adipocytes was downregulated by insulin, TNF-α, H2O2, and hypoxia; V5- tagged URB 
protein was secreted into culture media of Flp293 URB cells and endogenous URB protein 
was also detected in the media of human cultured adipocytes (ADSC-adipocytes). In the 
current study, like adiponectin, URB expression was reduced in with adipose tissue (WAT) of 
all three obese mouse models (ob/ob, KKAy, and DIO), while the expression levels of MCP-1 
and TNF-α were increased as reported previously. These data suggest a role for URB in 
metabolic syndrome.  
In another study [91] was shown that Ccdc80 is highly expressed in WAT and that its 
expression is regulated during adipocyte differentiation in vitro.  
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Using knockdown and overexpression studies, was found that Ccdc80 plays dual roles in 
adipogenesis by modulating C/EBPα and PPARγ expression. To confirm that Ccdc80 is a 
secreted protein, human Ccdc80 containing an in-frame C-terminal FLAG epitope was 
expressed in HEK293T cells. Examination of HEK293T supernatants by Western blotting 
using an anti-FLAG antibody showed that Ccdc80 is not only secreted in its full-length form 
(~108 kDa) but also as cleaved fragments of ~95 and ~50 kDa. Was next examined the 
temporal regulation of Ccdc80 gene expression during the differentiation of 3T3-L1 cells into 
adipocytes. Although classical adipokines such as leptin or adiponectin are up-regulated only 
during the terminal phase of adipocyte differentiation [92-93], Ccdc80 was expressed in a 
biphasic manner. Ccdc80 mRNA was relatively low in proliferating 3T3-L1 preadipocytes but 
increased almost 10-fold when cells reached postconfluence before the initiation of 
differentiation. The addition of adipogenic inducers (dexamethasone, IBMX, and insulin) led 
to a dramatic reduction in Ccdc80 expression, an effect that was observed as early as 8 h after 
the addition of the mixture and was maximal after 24 h. Ccdc80 mRNA levels increased again 
during the late stage of adipocyte differentiation. To determine which component of the 
adipogenic mixture was able to induce down-regulation of Ccdc80, was assessed the 
individual and combined contribution of various adipogenic inducers during the early stages 
of differentiation. The biphasic expression of Ccdc80 during adipocyte differentiation raised 
the possibility that Ccdc80 regulates adipogenesis. Indeed, although Ccdc80 immunostaining 
was significantly  reduced in Ccdc80 KD cells during both stages of adipocyte differentiation, 
the very few Ccdc80 KD cells that differentiate into adipocytes showed significant levels of 
Ccdc80. Furthermore, the addition of Ccdc80-containing medium to Ccdc80 KD cells was 
able to partially restore the ability of knockdown cells to differentiate into adipocytes. The 
authors also demonstrated that silencing of Ccdc80 was accompanied by decreased expression 
of genes involved in fatty acid uptake (e.g. lipoprotein lipase), triglyceride formation (e.g. 
diacylglycerol acyltransferase 1/2, lipin 1), and lipid metabolism. Expression of the 
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insulinsensitive glucose transporter GLUT4, a gene known to be upregulated during adipocyte 
differentiation [94], was also decreased in Ccdc80 KD cells, whereas expression of the basal 
glucose transporter GLUT1 was unchanged after Ccdc80 gene silencing. Interestingly, 
expression of several transcription factors that function early in adipogenesis, such as 
C/EBPβ, C/EBPδ, and cAMP-responsive element-binding protein 1, was unchanged, and 
expression of KLF5, a positive regulator of PPARγ gene expression [95], was increased in 
Ccdc80KDcells. These data suggest that Ccdc80 acts downstream of C/EBPβ/δ and KLF5, 
but upstream of C/EBPα and PPARγ. Since thiazolidinediones are potent inducers of 
adipogenesis [96], the addition of rosiglitazone (100 nM) to the adipogenic mixture increased 
differentiation in both control and Ccdc80 KD cells but did not restore differentiation of 
Ccdc80 KD cells to the same level as control cells. Given that increased expression of 
C/EBPα and PPARγ during adipogenesis requires down-regulation of Wnt/β-catenin 
signalling, the authors measured TOPFLASH activity as an index of β-catenin-mediated 
transcriptional activity via TCF, to determine whether modulation of canonical Wnt signaling 
might be involved in the phenotype of Ccdc80 KD cells. Moreover, Wnt10b, a secreted 
protein that has been shown to negatively affect adipocyte differentiation [97], is also 
expressed in a biphasic manner similar to Ccdc80 during adipogenesis. 
Upon reaching postconfluence, cells expressing a non-silencing or Ccdc80 shRNA displayed 
similar TOPFLASH activity. After induction of differentiation, TOPFLASH activity in 
control cells declined slowly, reaching ~50% of its initial activity after 4 days. In contrast, 
Ccdc80 KD cells showed a significant, ~2-fold increase in TOPFLASH activity compared 
with control cells as early as 1 day after induction of differentiation and maintained this 
difference throughout the 4-day period examined. In agreement with these observations, was 
found that several target genes of the Wnt/β-catenin signaling pathway (Axin-2, cyclin D1, 
Frizzled-7) were not significantly decreased after induction of differentiation in Ccdc80 KD 
cells, suggesting a failure to down-regulate Wnt/β-catenin signaling in these cells upon 
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induction of differentiation. Other data also suggest that Ccdc80 modulates the activity of the 
TCF transcriptional complex in a manner independent of Wnt10b and β-catenin and that 
endogenous Ccdc80 is both necessary and sufficient for repression of Wnt/β-catenin 
signalling during adipocyte differentiation. 
Because the effects of Ccdc80 are observed in the absence of any changes in β-catenin protein 
levels (in 3T3-L1 cells) as well as in cells expressing a constitutively active form of β-catenin 
(HepG2 cells), it is unlikely that Ccdc80 modulates TCF-mediated transcription by affecting 
upstream components of the Wnt/ β-catenin signalling cascade. Taken together, these data 
suggest a model (Figure 13) in which Ccdc80 positively modulates adipocyte differentiation 
by repressing the activity of the TCF transcriptional complex after induction of adipocyte 
differentiation. Ccdc80 also appears to play a negative role in adipogenesis by a mechanism 
that does not involve Wnt signalling repression. Achieving a balanced and timely expression 
of Ccdc80 throughout differentiation is essential for the induction and activation of C/EBPα 
and PPARγ and the acquisition of the adipocyte phenotype in 3T3-L1 cells. 
 
Figure  13 
Proposed mechanism by which Ccdc80 bidirectionally regulates adipogenesis 
 
A key finding of this study is that Ccdc80 is required for adipocyte differentiation and is 
regulated in a biphasic manner during adipocyte differentiation. This pattern of expression is 
distinct from classical secreted adipokines, such as adiponectin or leptin, but reminiscent of 
that of Wnt10b, a known adipocyte-secreted protein with an important role in adipogenesis. 
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In another study [98], a whole-body Ccdc80 knockout (KO) mouse was generated to 
investigate the function of Ccdc80 in glicemic balance. Was found that mice lacking Ccdc80 
are hyperglycemic and glucose intolerant and display impaired insulin secretion in vivo when 
fed a high fat diet. Transcriptional analysis revealed that some components of the molecular 
clock were altered in muscle, WAT, and pancreas of Ccdc80-/- mice. Furthermore, gene 
expression changes in the KO mice were associated with altered feeding behaviour, greater 
caloric intake, reduced energy expenditure, and obesity. 
In contrast to previous finding in 3T3-L1 cells [91], Ccdc80 does not appear to be required for 
normal WAT development as assessed by histology, as well as expression of PPARγ and 
adipocyte protein 2. Was also found no evidence that Ccdc80 was an important regulator of 
Wnt/β-catenin signaling in vivo as evidenced by unchanged expression of Cyclin D1 and 
Axin-2 between WT and Ccdc80-/- mice. Morphometrical analysis of WAT sections further 
revealed that adipocyte size was slightly larger upon HF feeding but was unaffected by the 
absence of Ccdc80. 
Fourthermore, Ccdc80-/- mice fed a HF diet had reduced insulin levels upon glucose 
administration that was associated with slightly albeit not significantly higher glucose levels. 
This impairment in glucose-induced insulin secretion in vivo  led to marked glucose 
intolerance in Ccdc80-/- mice fed a HF diet for 30 wk. In addition, Ccdc80-/- mice were 
found to be hyperglycemic at the end of the study. In contrast, glucose tolerance and glucose-
induced insulin secretion in vivo  in Ccdc80-/- mice fed a LF diet were virtually 
indistinguishable from their WT counterparts. Insulin tolerance tests further showed that 
peripheral insulin sensitivity was similar between WT and Ccdc80-/- mice, suggesting that 
defective in vivo insulin secretion was responsible for the glucose intolerance observed in HF-
fed Ccdc80-/- mice. In an attempt to determine the mechanisms underlying the metabolic 
abnormalities associated with Ccdc80 deletion in mice, was performed a transcriptional 
profiling analysis by microarray of skeletal muscle, pancreas, and WAT from WT and 
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Ccdc80-/- mice fed either a LF or HF diet. Although numerous unique transcripts were 
regulated by Ccdc80 in each of the tissues examined, only 10 were simultaneously regulated 
by the deletion of Ccdc80 in all three tissues. Initial examination of these transcripts revealed 
that four of them, representing three different genes, were components of the circadian clock. 
Because of the prominent role of circadian rhythms in metabolic control, it is possible that 
altered expression of Arntl (also known as Bmal1), Dbp, and Tef contributes to the metabolic 
phenotype of Ccdc80-/- mice. Although the exact mechanism by which disruption of Ccdc80 
affects the expression of Arntl, Dbp, and Tef is not known, our study in 3T3-L1 cells provide 
evidence that Dbp biphasic expression is regulated, at least to some extent, in a cell-
autonomous manner by Ccdc80. Importantly, silencing of Ccdc80 led to a reduction in Dbp 
and, to a lesser extent, Tef expression before induction of adipocyte differentiation, 
suggesting that these changes were not due to the impaired adipogenesis phenotype of the 
knockdown cells. 
As above mentioned, this study shows that Ccdc80 is not required for normal WAT 
development in vivo as evidenced by unchanged adipocyte morphology and size, as well as 
PPARγ and adipocyte protein 2 expression in Ccdc80-/- mice. Was also not find evidence that 
Ccdc80 was an important modulator of canonical Wnt signaling and expression of Wnt target 
genes, at least in WAT, skeletal muscle, and pancreas. This is in contrast to previous findings 
in 3T3-L1 adipocytes in which Ccdc80 was shown to act as a repressor of Wnt/β-catenin 
signaling during differentiation [91] as well as findings in cancer cell lines that established a 
connection between Ccdc80 expression and Wnt signalling [69-71]. The reason for this 
discrepancy is not clear but might indicate that Ccdc80 regulates Wnt signaling during 
development and neoplastic transformation but not in terminally differentiated cells from 
adult mouse tissues. Fourthermore, was show that absence of Ccdc80 exacerbates diet-
induced glucose intolerance and hyperglycemia in mice fed a high fat (HF) diet. The inability 
of KO mice to maintain normal glucose homeostasis appeared to be due to defective glucose-
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induced insulin secretion. However, no major morphological and biochemical changes were 
detected in pancreas from Ccdc80-/- mice. Furthermore, pancreatic islet hypertrophy in 
response to HF feeding was similar between WT and Ccdc80-/- mice, suggesting that other 
mechanisms underlie the defective insulin secretion that is observed upon glucose challenge 
in the KO mice. 
Moreover, in another study [99], using a yeast 2-hybrid screen of an adipocyte cDNA library, 
Ccdc80 was identified as a novel JAK2-binding protein. The Janus family of tyrosine kinases, 
which includes Janus kinase 1 (JAK1), JAK2, JAK3, and Tyk2, plays a critical role in 
signaling by members of the cytokine superfamily of receptors. JAK2 is activated by more 
than two-thirds of these receptors, including the receptor for GH, prolactin, erythropoietin, 
leptin, leukemia inhibitory factor, interferon-γ, and multiple interleukines (ILs). JAK2 
promotes the growth, proliferation, and/or differentiation of many cell types, and 
dysregulation of JAK2 has been linked to various forms of cancer [100-101]. 
Despite the fact that JAK2 is necessary for signalling by multiple cytokines, hormones, and 
growth factors [102] and is the most studied of the JAKs, only a handful of proteins have been 
identified that bind directly to JAK2. The authors in this paper show that Ccdc80 binds to the 
active tyrosylphosphorylated form of JAK2 but not the inactive form of JAK2 and that in the 
presence of active JAK2, Ccdc80 is also phosphorylated. Binding to JAK2 requires the 
regions in Ccdc80 that are homologous to domain 5 of the sushirepeat-containing protein, X-
linked (SRPX) and in mammalian systems also SRPX2 binds preferentially to activated 
JAK2. These results suggest that the DUDES protein interaction domain characterizes a novel 
class of proteins that bind activated JAK2. Regarding function, Ccdc80 does not enhance 
JAK2 kinase activity, however Ccdc80 stimulates the phosphorylation of Stat5b on Tyr699, 
which is required for Stat5b activation, and enhances Stat3 phosphorylation. Finally, was 
shown that Ccdc80 has a functional signal peptide and that a portion of Ccdc80 is secreted 
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into the extracellular compartment where it both associates with the extracellular matrix and is 
released into the medium. 
Importantly, in this article the authors provide a different size and sequence of Ccdc80 as a 
protein of 949 aa (110 kDa) that resulted identical to rat DRO1 [70] and rat CL2 [71]. 
Because Ccdc80 has a wide tissue distribution, and JAK2 is activated by nearly two-thirds of 
the cytokine receptors, it seems likely that Ccdc80 plays a role in not only GH signalling but 
also signalling by other ligands that bind to members of the cytokine receptor family. 
Consistent with this hypothesis, in the bombesin-receptor-subtype (BRS)-3–deficient model 
of obesity, the brown adipose tissue is characterized by elevated Ccdc80 levels, suppressed 
GH levels, and dramatically elevated leptin levels [69, 103]. An inhibitory role for Ccdc80 on 
leptin signaling would be consistent with the apparent leptin resistance detected in these mice. 
Moreover, because Ccdc80 binds JAK2 and coexpression of Ccdc80 with JAK2 elevates 
phosphorylation of Stat3 and Stat5, suggest that Ccdc80 functions in the intracellular 
compartment. Ccdc80 contains a putative signal peptide, the hallmark of a protein destined for 
processing by the endoplasmic reticulum/Golgi and secretion. Indeed, was observed that 
Ccdc80 localizes to the perinuclear region of the cell and comigrates with markers for the 
endoplasmic reticulum and Golgi [70, 86], is secreted from the cell [76, 90], binds to the 
extracellular matrix [68, 76, 84], and, once secreted, is cleaved into several fragments [68, 70, 
90, 91]. However, not all cells that express Ccdc80 secrete Ccdc80. 
 
4.8 Ccdc80 in cardiac and skeletal muscle 
As abovementioned, it is demonstrated that Ccdc80 in abundantly expressed in heart and 
skeletal muscle and it is also proved that Ccdc80 is highly expressed in skeletal myotubes 
during differentiation [104]. Moreover, microarray data demonstrate the suppression of its 
expression in starved myotubes (Figure 14) and the increased expression in muscles from 
patients affected by Duchenne dystrophy [105] (Figure 15): taken together, these data suggest 
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a possible role of Ccdc80 as a cell differentiation protein both in cultured cells and muscle 
tissues undergoing regeneration or remodelling. 
 
Figure 14 
Comparison of Ccdc80-RNA expression in normal and starved myotubes, from NCBI GEO database.  
 
 
 
 
Figure  15 
Comparison of Ccdc80-RNA expression in normal  muscle and in patients with Duchenne muscolar 
dystrophy, from NCBI GEO database [105]. 
 
 
On the other side, the only data available in literature, about normal cardiac expression of 
Ccdc80, have evaluated the expression profile of Ccdc80-RNA in atria and ventricles (Figure 
16). 
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Figure  16 
Ccdc80-RNA in heart of RNA from human cardiovascular tissues, from NCBI GEO database.  
In the right part is shown Northern blot analysis [106]. 
 
Regarding a possible role of Ccdc80 in cardiomyopathies, are currently available only two 
gene expression profile studies, which compared samples from DCM to non-failing pairs, and 
to ischemic cardiopathy, identifying Ccdc80 as a clear-cut upregulated gene in diseased 
tissues (Figure 17). 
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Figure  17 
Comparison of Ccd80 RNA expression in normal heart and cardiomyopathies (DCM and ischemic),  
from NCBI GEO database  
 
Another study [106] identified steroid-sensitive gene 1 (SSG1, an ortologue of  Ccdc80) as a 
novel protein kinase G (PKGI) substrates: in vascular cells, a λ-phage coronary artery smooth 
muscle cell library was constructed and screened for phosphorylation by PKGI. The screen 
identified SSG1, which harbours several predicted PKGI phosphorylation sites. Was observed 
direct and cGMP-regulated interaction between PKGI and SSG1 and in vascular smooth 
muscle cells, both the NO donor S-nitrosocysteine and atrial natriuretic peptide induced SSG1 
phosphorylation, and mutation of SSG1 at each of the two predicted PKGI phosphorylation 
sites completely abolished its basal phosphorylation by PKGI. This study confirmed the 
highest SSG1 expression in the heart, followed by skeletal muscle and colon. Lower 
expression levels were observed in the thymus, spleen, kidney, liver, small intestine, placenta, 
and lung. PKGI inhibits VSMC contractility by regulating signalling pathways that control 
myosin phosphorylation and by modulating the level of intracellular calcium and by altering 
the sensitivity of the contractile apparatus to calcium [107]. PKGI and cGMP inhibit left 
ventricular remodeling in response to pressure overload [108-109], although the downstream 
PKGI effectors in the myocardium remain incompletely understood. Interestingly, left 
ventricular pressure overload modulates cardiac SSG1 expression [110]. 
Overall, the abovementioned results suggest multiple roles of the Ccdc80 gene in the different 
species investigated, during embryonic development and adult life, for adipocyte 
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differentiation, metabolic regulation, cancer development as well in muscle tissues 
undergoing regeneration or remodelling; they also indicate that Ccdc80 exerts its function in 
different intracellular and extracellular compartments.  
 
5. Materials and methods  
Giving the aims of our investigation, we used different models:  
1. Zebrafish model, to define the functional role of Ccdc80 in embryonic development: 24 
controls and 42 zebrafish morphants, injected with the Ccdc80 antisense morpholino; 
2. Rat model: 6 controls compared with 6 samples of right ventricle heart failure induced by 
intraperitoneal monocrotaline injection; 
3. Human model: 2 controls (donor healthy hearts which were not transplanted for logistic 
problems), compared with 14 samples of patients affected by dilated cardiomyopathy.  
4. Skeletal muscle: 2 samples of normal intercostals human skeletal muscle were compared to 
2 samples of patients affected by Duchenne muscular dystrophy. 
 
5.1 Rat model of heart failure 
Right ventricular heart failure was induced in male Sprague-Dawley rats (90 to 100 g) by 
intraperitoneal injection of 30 mg/kg monocrotaline (MCT) according to Vescovo et al. [111]  
Our rat samples were derived from a previous study [112]: after 21 days, a time-point when 
pulmonary hypertension is present and right ventricular hypertrophy and failure begin to 
develop, the rats were sacrified. 
A second group of rats injected with Dulbecco’s modified Eagle medium (DMEM), but 
without MCT, serving as a control without right ventricular heart failure. 
MCT [113] is a pyrrolizidine alkaloid found in the foliage of Crotalaria spectabilis. Ingestion 
of MCT has been associated with hepatic and pulmonary disease in humans and many animal 
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species. In rats, a single administration of MCT results in pneumotoxic changes that are 
delayed in onset and progressive [114]. These include pulmonary vascular leak, pulmonary 
arterial vascular remodelling, and pulmonary hypertension. Pulmonary damage is not caused 
directly by MCT but by its metabolic products. Monocrotaline is converted to reactive 
pyrroles by the mixed function oxidase system of the liver, but not of the lungs [115-116]. It 
is presumed that small quantities of these pyrrolic metabolites escape binding in the liver and 
travel via the blood stream to the pulmonary vascular bed, where they bind covalently to 
cellular macromolecules [117]. Monocrotaline pyrrole (MCTP) is an unstable, electrophilic, 
putative metabolite of MCT. When a single injection of a low dose of chemically synthesized 
MCTP is injected into tail veins of rats, delayed and progressive pulmonary injury, pulmonary 
hypertension, and right heart hypertrophy results that is similar to that induced by MCT itself 
[118].  
All these changes in pulmonary vascular bed leads to pulmonary hypertension, right 
ventricular hypertrophy and right ventricular failure. This kind of right ventricular heart 
failure induced by MCT is a well established model, which mimics the congestive heart 
failure syndrome in man. The paraffin-embedded tissue were analyzed with Haematoxylin 
and Eosin (H&E), immunohistochemistry and immunofluorescence staining.  
 
5.2 Zebrafish 
Besides the traditional rodent and invertebrate models, zebrafish (Danio rerio) has been used 
since the early last century as a classical developmental and embryological model. Zebrafish 
has emerged in the last past decades as an effective model organism for biomedical research 
due to the unique combination of the optical clarity of the embryos, allowing in vivo 
observation of cell-biological events and the rapid development in 24 hours of all the 
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differentiated tissues. In addition is well known that the zebrafish homolog of human Ccdc80 
shows a high similarity. 
Giving also that zebrafish is able to survive during embryonic development without a 
functional cardiovascular system, this model appears particularly useful for the study of  
functional role of proteins in heart development.  
The Zebrafish strains used are obtained from ZIRC, Oregon US, and from Wilson lab, University 
College London. 
Adult fish were maintained at 28.5 C, 14 hours light/10 hours dark cycle, in a recirculating fresh 
water system according to standard procedures.  
Embryos were raised at the same temperature as adults in Petri dishes with a change of water 
twice / day. Fish were fed every day with brineshrimps, Artemia salina, (living or frozen) and 
Small Granular feed from Zebrafish Management Ltd., England.  
Embryos were obtained from natural spawning and, starting from 24 hours post fertilization (hpf), 
were treated with 0,003 % 1-phenyl-2-thiourea (Sigma-Aldrich) for avoiding pigmentation. 
Embryos were staged in hours post fertilization and by counting somites numbers according to 
Kimmel et al. [119]. For a better observation embryos were anesthetized in 0,0016 % Tricaine 
(MS-222, Sigma-Aldrich).  
 
5.2.1 RNA extraction and purification  
The full-length sequence of the Ccdc80 mRNA was cloned as reported by Visconti et al. and the 
sequences at the 5’ and 3’ Untranslated Regions (UTR) of the Ccdc80-mRNA were identified, 
amplified and cloned.  
For the 5’ end identification and cloning the following oligonucleotides were used: forward  
5’- GCGAATTCGATTTGTCTTTGTTAAAAACTAT – 3’,  
and reverse 5’ - GACGCCAGTAGTTTGGAGAACC - 3’. For the 3’ end identification and 
cloning the following oligonucleotides were used: forward  
5’ – GGCCATCCAGCAGTCTCTAGG - 3’,  
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and reverse 5’ – TAAGGATCCGACCACGCGTATCGATGTCGAC -3’.  
The UTR sequences obtained from the RACE have been analysed with the ABI PRISM® 310 
Genetic Analyzer (Applied Biosystems), using the oligonucleotides indicated by the RACE kit 
manufacturer for the Cycle Sequencing reaction, which was performed according to 
manufacturer’s instructions.  
The analysis of all the possible reading frames of the amplified putative CDR sequence revealed 
that one single ORF was present. The starting codon was located in the first position of the 
amplified sequence (ATG) and the stop codon (TAG) in the last position of the amplified 
sequence, giving a coding region of 2604 bp. Also in the 5’ ending sequence, identified using the 
RACE technique, were not found alternative starting codons located in frame with the putative 
CDR sequence. These results let us bona fide consider that the full-lenght sequence we have 
cloned, contains the full CDR sequence of the Ccdc80 gene, and that the 5’and 3’ amplified 
sequences can be considered the UTR of the Ccdc80 gene.  
Physico-chemical properties of the Ccdc80 protein were deducted in silico by the analysis of the 
amino acidic sequence with the software program Compute pI / Mw.  
The putative sub-cellular localization of the Ccdc80 protein was predicted using the software 
program WoLF PSORT.  
The presence of common motifs in the Ccdc80-encoded protein was analyzed with the software 
program MEME, and the software program Motif Alignment and Search Tool analysis (MAST). 
Alignment of the three obtained domains was performed with the software program ClustalW2.  
Samples were treated as follows:  
Adult fish were quickly frozen in liquid nitrogen and stored at -80 C until further processing. Eggs 
were cleared from medium, snap frozen in liquid nitrogen and stored at -80 C until further 
processing. For the purification of total RNA from adults organs, adult fish were anesthetized in 
0,0016 % Tricaine (MS-222, Sigma-Aldrich) until no opercula movement was reached. Organs 
were then rapidly dissected under a stereomicroscope, quickly frozen in liquid nitrogen and stored 
at -80 C until total RNA extraction. Frozen specimens were gently homogenized in TRIZOL® 
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(Invitrogen), a mono-phasic solution of phenol and guanidine isothiocyanate which maintains 
RNA integrity while allowing tissues and cells lysis during homogenization. After 
homogenization, addition of chloroform followed by centrifugation induced the separation 
between an organic phase and an aqueous phase, which contained the total RNA. It was then 
recovered by precipitation with isopropyl alcohol, then washed in 75 % ethanol and suspended in 
DEPC treated water.  
It was purified from total RNA with the NucleoTrap mRNA Mini Purification kit (Macherey-
Nagel) which allows the purification of mRNA by means of a spin-column filter combined with 
an oligo(dT)-latex bead suspension technology. Manufacturer’s instructions were followed with 
minor modifications.  
After purification total and poly A
+ 
RNA were photometrically quantified and analyzed for purity.  
 
5.2.2 Semi-quantitative PCR analysis  
A semi-quantitative PCR analysis was performed in order to evaluate the temporal expression of 
the Ccdc80 gene during the embryo development, and in organs from adult fish.  
At this purpose 0.5 µg of total RNA, extracted as described in the section 2.4.1 from embryos at 
several developing stages and adult organs was used as the template in a reverse transcription 
reaction using random primers and the AMW-Reverse Transcriptase (Roche). 1 µg of the cDNA 
was used in a PCR reaction (Taq DNA Polymerase, Eppendorf) performed at 25 cycles with the 
aim to not reach the reaction plateau, but to remain in the exponential reaction phase. In order to 
have a standard for the normalization of the data, the costitutively expressed enlongation factor 1 
alpha (EF1α) gene was also tested in a parallel PCR. The reaction program was the following: 
initial denaturation, 2 min at +94 C, followed by denaturation, 30 s at +94 C – annealing, 45 s at 
+60 C – enlongation, 60 s at +72 C, for 25 cycles, and a final enlongation of 7 min at +72 C.  
The Ccdc80 amplicon was a sequence of 379 bp in size and spanning between the exon 3 and the 
exon 6 of the Ccdc80 transcript.  
The oligonucleotides used as the primers were the following:  
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Ccdc80 amplicon: 5’- CCAGGATCTCATCATGGAGC –3’,  
and 5’- GACCAGCTTCAGCACGGACA -3’.  
EF1α amplicon: 5’- GGTACTTCTCAGGCTGACTGT –3’,  
and 5’- CAGACTTGACCTCAGTGGTTA –3’.  
10 µl of each PCR product were then electrophoresis runned on an agarose gel and blotted on a 
nylon Zeta-Probe GT membrane (Biorad). The blots obtained were hybridized with the same PCR 
products as the probes, which were labeled with [α-
32
P]dCTP, Amersham (Random Primed DNA 
Labeling Kit, Roche). After hybridization, blots were exposed to a T-MAT G/RA (Kodak) film 
for the detection of the PCR product bands, on which we performed a densidometric analysis with 
the Quantity One software program, BioRad.  
 
5.2.3 Morpholino knocking-down 
The antisense MO for the Ccdc80 knocking-down (Ccdc80-morpholino, MO Ccdc80) was 
obtained from Gene Tools, Philomath, Oregon, US. It is a translational-blocking morpholino 
having the following sequence: 5’-AACCAAGCATATACCGTGCCCTCAT-3’. A 5-mismatch 
morpholino designed against the same region was used as the control for unspecific effect:  
5’-AAgCAAcCATATAgCGTGCgCTgAT-3’.  
Different doses of each MO were used for testing morphological effects on embryos and/or for 
possible effects on the expression of specific molecular markers. The final dose for all the 
subsequent tests was 1 pmol/embryo.  
As the control for unspecific effects, each knocking-down experiment was performed in parallel 
with injection of the same amount of a standard control oligo morpholino with no target in 
zebrafish and obtained from Gene Tools, Philomath, Oregon, US.  
Rescue experiments were performed to assess the specificity of the CL-morpholino knocking-
down.  
The specific action of CL-morpholino in blocking the Ccdc80 transcript was evaluated with the 
co-injection of MO Ccdc80 at the dose of 1 pmol/embryo, together with different doses of the 
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synthetic full-length Ccdc80 mRNA. The full rescue was reached with the injection of 400 pg of 
Ccdc80 mRNA, as it was evidenced by in vivo morphological and WISH analyses of injected 
embryos. In vivo observations were performed during somitogenesis, at 24 hpf, and 48 hpf, and 
the WISH analyses were performed to evaluate myoD and cmlc 2 expression patterns at the stage 
of 8-10 somites and 48 hpf, respectively.  
 
5.2.4 Whole-Mount In Situ Hybridization (WISH) 
With the aim to detect the mRNA transcript of genes of interest in morphologically conserved 
whole embryos, Whole-Mount In Situ Hybridization (WISH) reactions have been performed in 
embryos at different developing stages. In the WISH technique, antisense RNA labeled probes are 
used that can specifically bind a corresponding sequence of the transcript under investigation, thus 
allowing its spatial localization in the whole embryo. Sense RNA probes for the same transcript 
sequences were also tested for aspecific bindings.  
 
All the probes were cloned in a plasmid containing the promoters for an in vitro reverse 
transcription reaction. They were synthesized from the linearized plasmid and were labeled with 
the digoxigenin molecule using the DIG RNA Labeling kit, Roche, according to manufacturer’s 
instruction. Labeled probes were purified with the High Pure RNA Isolation kit, Roche, quantified 
on an agarose gel, and used in the WISH at a concentration of 1 µg/ml.  
The probe used for the Ccdc80 transcript detection corresponds to the first 1125 bp of the CDR. 
For its application in WISH, it has been previously cloned in the pcDNA3 plasmid, which has the 
suitable T7 and SP6 promoters for the DIG riboprobes synthesis. For the antisense probe 
synthesis, plasmid was linearized with EcoRI restriction endonuclease and the reverse 
transcription was made with T7 RNA polymerase. For the sense control probe synthesis, plasmid 
was linearized with BamHI restriction endonuclease and reverse transcribed with SP6 RNA 
polymerase.  
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The other probes were already present in our lab as markers commonly used for the analysis of 
embryonic specific regions.  
Embryos were raised as described in section 2.1, fixed in 4 % paraformaldehyde (PFA), manually 
decorionated in Phosphate Buffer Saline (PBS) solution and moved through methanol/PBS graded 
series to 100 % methanol for permeabilization and possible long storage, at -20 C.  
The hybridization protocols for the WISH reactions were optimized for each probe and/or 
developing stage.  
After hybridization, probes were immunologically detected using anti-digoxigening Fab 
fragments from sheep specific IgG, conjugated with alkaline phosphatase (Anti-Digoxigenin-AP, 
Fab fragments, Roche), and the NBT/BCIP (Roche) phosphatase substrates for a colorimetric 
detection. The phosphatase reaction gave a water insoluble dark blue precipitate, which could be 
observed in a variable time from few minutes to few days according to the developing stage and 
the expression level of the transcript under investigation. After detection embryos were post-fixed 
in 4 % PFA and stored in PBS/EDTA at +4 C in the dark.  
Embryos were then observed under the Leica MZ16F stereomicroscope and images have been 
acquired with the Leica DFC 480 digital camera and the IM500 software program (Leica 
Microsystems).  
WISH protocols used were the Patterson protocol [120] and an high resolution protocol [121]. 
Cardiac specific markers were evaluated by WISH in Ccdc80-silenced embryos, in particular 
Nkx2.5 [122], Cmlc 2 [123], Amhc [124], HrT [125]. 
 
5.2.5 Histological analysis 
Embryos were dehydrated through an ethanol/PBS graded series to 75% ethanol and their yolks 
were gently mechanically dissected. Embryos cleared from yolk were then treated as follows:  
- 5 min 90% ethanol;  
- 5 min 95% ethanol;  
- 5 min 100% ethanol (twice);  
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- 5 min 100% xylol;  
After this, embryos were flat mounted over a microscope slide in a 50% xylol and 50% Eukitt 
(Bio-optica) mounting medium. After this, they were observed under the Olympus BH-2 
polarizing microscope and image analyzed with the (Olympus C-35AD-4) camera.  
 
Embryos were dehydrated through a PBS/ethanol graded series to 90% ethanol. Then washed 
again in 90% ethanol and washed twice for 15 minutes in xylol. After this they were washed in 
liquid paraffin over night at +40 C. After this, old paraffin was replaced with new one every hour 
for three times. Then embryos were placed in the moulds, oriented and let to get cold at room 
temperature for few hours, finally moved at +4 C over night. 0.8 µm sections were cut under the 
microtome Microm HM360 and let to dry at +40 C over night. After this, slides were treated as 
follows:  
Deparaffination  
- 15 min in xylol;  
- 5 min. in xylol;  
Hydration  
- 2 min. absolute ethanol, twice;  
- 2 min 95% ethanol;  
- 1 min 90% ethanol;  
- 1 min 70% ethanol;  
- 1 min 50% ethanol;  
Staining  
- 1 min eosin;  
Wash  
- 1 min distilled water;  
- 1 min tap water;  
- 1 min distilled water;  
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Dehydration  
- 2 min 50% ethanol;  
- 2 min 70% ethanol;  
- 2 min 90% ethanol;  
- 2 min 95% ethanol;  
- 2 min absolute ethanol (twice);  
Mounting pre-treatment  
- 2 min xylol;  
- 5 min xylol.  
Slides were then mounted with the Eukitt (Bio-Optica) mounting medium, observed under the 
Leica DM6000 B microscope equipped with the Leica DCF480 digital camera, and analyzed with 
the software program LAS (Leica Application Suite). 
 
5.3 Immunohistochemistry and immunofluorescence 
Fluorescence and Chromogenic Immunohistochemistry and Confocal Analysis were made as 
follows: 
Several antibodies (Abs) were used, alone or together, smooth muscle cells antibody (Dako, 
dil 1/200); Myosin antibody (alfa mouse slow muscle-myosin, Chemicon, dil: 1/200); 
Troponin I antibody (clone H-170, rabbit polyclonal, dil:1/100); Fibronectin (clone P5F3 
mouse monoclonal, dil: 1/100), Tropomyosin (clone CH1, mouse monoclonal, Santa Cruz, 
dil:1/100). Was used polyclonal anti-Ccdc80 antibody produced in rabbit (Sigma-Aldrich, 
Milan, Italy) at dilution 1/20. 
Briefly, slides were treated with 0.3% hydrogen peroxide in methanol to block endogenous 
peroxidase activity, then washed with phosphate-buffered saline and incubated in buffered 
normal horse serum to prevent nonspecific Ab binding. Sections were incubated with the 
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primary Abs for 1 hour at room temperature. After washing, a biotin-labeled secondary Ab 
was applied, followed by an avidin-peroxidase conjugate. Diaminobenzidine was used as a 
chromogen. 
Immunostaining was done simultaneously with Ab against Ccdc80 coupled with other 
antibodies, visualizing the outcome with anti-mouse or anti-rabbit fluorescein isothiocyanate– 
or rhodamine-conjugated secondary Abs. Nuclei were stained with TO-PRO 3 
(Invitrogen,Molecular Probes; distributed by Invitrogen, Milan, Italy). Microphotographs 
were taken using a TCS-SL laser scanner confocal microscope (Leica, Wetzar, Germany). 
The parameters of wavelength detected for each fluorophore is as following: for FITC/ 
Spectrum Green fluorophore Ex 480/30, for Spectrum Orange fluorophoreEx 535/50. 
A control positive section of tonsil or bone marrow biopsy from autopsies was included for 
each Ab in each immunostaining session. 
 
5.4 Northern Blot 
Total RNA and mRNA poli (A)
+
 were denatured by treatment with formamide, fractionated by 
electrophoresis through a denaturing agarose gel containing formaldehyde, then transferred on a 
nylon Zeta-Probe GT membrane (Biorad). As the negative control the total RNA from rat lung, in 
which no Ccdc80 expression has been previously detected (data not shown), was used.  
The blot obtained was hybridized with a specific probe for the detection of the Ccdc80 gene 
transcripts.  
The probe was 1140 bp and located between the 5’UTR region and the first exon of the gene. It 
was PCR amplified using the following oligonucleotides as the primers:  
5’-TTAGAATCCGCCACCATGAGGGCACGGTA –3’ and  
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5’- GGCTGGGATCCATTGAGGGGTAGTA – 3'. After purification the PCR product was radio 
labeled with [α-
32
P]dCTP, Amersham (Random Primed DNA Labeling Kit, Roche) and used as 
the probe. After hybridization the blot was exposed to a T-MAT G/RA (Kodak) film for the 
detection of the bands corresponding to the Ccdc80 transcripts. 
 
5.5 Western Blot  
Protein extraction from formalin-fixed and paraffin embedded (FFPE) tissues were made as 
follows: 
4 µm sections of atria and ventricle of each sample were cut and placed in 1.5 mL 
microcentrifuge tubes. Sections were deparaffinized through two changes of xylene, followed 
by dehydration in graded ethanol/xylene, vortexed and centrifugated. 
Surnatant was collected and place in a 1.5mL microcentrifuge tubes containing sodium 
dodecyl sulfate (SDS) buffer with 5% β-mercaptoetanol and digested at 90oC. 
Surnatants were collected and place at -20oC until use. 
Polyclonal anti-Ccdc80 antibody produced in rabbit (Sigma-Aldrich, Milan, Italy) at dilution 
1/20 was used. 
Protein concentration was determined using The Qubit® Protein Assay Kit (Life 
Technologies, Milan, Italy) designed specifically for use with the Qubit® Fluorometer (Life 
Technologies, Milan, Italy), according to the manufacturer’s instructions. 
1-Dimensional (1-D) Gel Separation and western blot analysis of Ccdc80 were made as 
follows: 
Twenty micrograms of protein lysate from each sample were run on 4–10% Criterion TGX 
Stain-Free Precast Gels (BioRad, Milan, Italy) and transferred to nitrocellulose membranes 
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(Applichem, Milano, Italy) following the manufacturer’s instructions. Membranes were 
blocked in TBST buffer with 5% low fat-milk for two hours and incubated with anti- Ccdc80 
antibody (1:250, Sigma-Aldrich, Milan, Italy) at 4oC, overnight and probed with Cy5-
coniugate goat anti rabbit IgG (1:1000,KPL, Prodotti Gianni, Milan, Italy) 1 hour at room 
temperature. 
All western blot were visualized  using Alliance 2.7 gel analyzer (UVITEC Cambridge, 
Eppendorf, Italy) and CHROMA RED channel for fluorescence signals. 
The percent distribution of the fluorescence signals was determined by a densitometric 
software (Alliance 2.7 1D software, UVITEC, Eppendorf, Italy) after image acquisition of the 
stained gels. 
 
6. Results          
6.1 Functional role in Zebrafish 
Semi quantitative RT-PCR analysis on adult tissues (Figure 18) shows that Ccdc80 is 
expressed in all the analyzed tissues. In particular, it is expressed in heart at the highest level, 
and in liver and intestine at the lowest level. Intermediate levels are evident in brain, ovarian 
tissue and the surrounding fat tissue, mesonephric duct, swim bladder, pancreas. 
           
Figure 18 
Zebrafish CL2 (Ccdc80) expression in adults 
 
 
Semi-quantitative RT-PCR analysis was performed on embryos at different developing 
stages. Starting from 1-2 cells, and up to 106  hpf, Ccdc80 transcript is detectable in all the 
developing stages considered. It is present at high level since the one-cell stage and its 
 49 
expression remains nearly constant during the cleavage and the blastula period. Then it 
decreases and remains at low level in the gastrulation period. During somitogenesis the 
Ccdc80 mRNA level increases gradually, and reaches a peak at 22 somites.  
        
Figure 19 
Zebrafish CL2 (CCDC80) expression analysis during embryonic development 
 
 
WISH analysis was performed on embryos at the same developing stages as the quantitative 
PCR, with the aim to define the localization of the Ccdc80 transcript in the whole embryos 
during development. The antisense Ccdc80 ribo-probe used to detect the Ccdc80 mRNA in 
the whole embryos demonstrates that during the cleavage and blastula periods it is 
homogeneously expressed in all the blastomers. 
The same occurs in the gastrula period at lower level. In the segmentation period, starting 
from the stage of 7-8 somites up to late somitogenesis, Ccdc80 transcript is localized in the 
notochord. After somitogenesis is completed, the signal begins to decrease in a rostral-to-
caudal direction. At 24 hpf the transcript is still detectable in the caudal portion of the 
notochord, in the heart tube, dorsal aorta and its cephalic roots, in the caudal vein, and in the 
tail bud. At 48 hpf the Ccdc80 transcript is still faintly detectable in the notochord, it is still 
present in aorta (including aortic arch) and caudal vein at a lower level and it appears in the 
inter-somitic caudal vessels. In the heart, is particularly evident in the atrio-ventricular 
junction and in bulbus arteriosus (Figure 20) Finally, it appears in the fin buds. At 72 hpf the 
Ccdc80 transcript is still detectable in heart, dorsal aorta, and barely in the caudal vein and 
caudal inter-somitic vessels; a signal is present also in the cephalic region, in both the cranial 
cavity and musculature, and in the region surrounding the notochord. At 120 hpf the 
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expression is still evident in heart, appears in body muscles, in the swim bladder, and in the 
eye. 
 
Figure 20  
In vivo observation of developing embryos in the hatching at 48, 72 and 120 hpf 
A: embryo at 48 hpf. red arrow: aortic arch; green arrow: atrio-ventricular junction; black arrow: bulbus 
arteriosus. B: embryo at 72 hpf. Yellow arrow: atrium; green arrow: atrio-ventricular junction.  
C: embryo at 120 hpf. Yellow arrow: atrium. 
 
The first phenotypical alteration can be observed in morphants during the segmentation 
period. In comparison to controls, at least 62% of the Ccdc80-morphants show multiple 
defects in the forming somites. Somites morphology is heterogeneously disorganized, with 
the loss of the proper shape. Somites can appear flat, “packed”, enlarged, with the presence of 
adjunctive boundaries (sub-segmentated), or without the proper boundaries. The second in 
vivo phenotypical alteration in Ccdc80-morphants can be observed in the pharyngula period 
of development, at 24-26 hpf. Although in Ccdc80-morphants the differentiated somites seem 
almost completely recovered and the embryos show proper motility, at this developing stage 
65% of the Ccdc80-morphants show curved tails. In the hatching period, at 48 hpf, Ccdc80-
morphants show defects in the developing heart, with a general enlargement of the atrium 
(figure 21). Moreover, edemas can be observed in the pericardial cavity, and in the cranial 
cavity. At 72 hpf, Ccdc80-morphants show similar, but more severe cardiac defects with 
respect to the previous developmental stage, with persistent edemas. Moreover, in the altered 
Ccdc80-morphants, blood stasis is evident in the sinus venosus region (Figure 22). Tails 
present an extremely heterogeneous morphology. They appear from nearly straight, to bent or 
curved, both convex and concave, also in the same injected batch of Ccdc80-morphants.  
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Figure 21  
In vivo observation of developing embryos in the pharyngula (24 hpf) and hatching (48 hpf) periods  
In vivo images of embryos injected with 1 pmol of the CL2 (Ccdc80) antisense morpholino and controls. Arrows 
indicate region of interest highlighting defects observed in morphants with respect to controls.  
A-B: 24 hpf embryos. C-L: 48 hpf tg(flk1:G-RCFP) embryos. A, B, C, D, G, H: bright-field. E, F, I, L: 
fluorescence. A, C, E, G, I: controls. B, D, F, H, L: morphants. B: curved tail. G, H, I, L: the same embrios as 
in C, D, E, F, at higher magnification. Morphants show edemas and the atrium enlargement  
 
 52 
 
 
 
Figure 22 
In vivo observation of developing embryos in hatching period (72 hpf)  
In vivo images of tg (fli1:EGFP)y1 embryos at 72 hpf, injected with 1 pmol of the CL2 (Ccdc80) antisense 
morpholino and controls. Arrows indicate region of interest highlighting defects observed in morphants with 
respect to controls. A, B, E, F: bright-field. C, D, G, H: fluorescence. A, C, E, G: controls. B, D, F, H: 
morphants. E, F, G, H: the same embrios as in A, B, C, D, at higher magnification. Morphants show high atrium 
enlargement with severe edemas, and the enlargement of pericardial chamber. 
 
 
Cardiac specific markers were evaluated by WISH in Ccdc80-silenced embryos: 
 
Nkx2.5 is normally expressed in the cardiac precursor cells at 8-10 somites, when the 
mesodermal cardiac field is committed. In most of the Ccdc80-silenced embryos its 
expression is properly patterned (Figure 23). 
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Figure 23 
Nkx2.5 expression in silenced CL2 (CCDC80) embryos at 8-10 somites  
A-E: nkx2.5 expression pattern analyzed by Whole-Mount in situ hybridization. Embryos at 8-10 somites, 
injected with Ccdc80 morpholino (C-E), and controls (A, B ) are shown. Dorsal view, anterior is up. A: controls 
with no alterations. B: controls with minimal alteration. C: morphants with no alterations. D-E: morphants with 
minimal alteration. 
 
Cmlc 2 was investigated in Ccdc80-silenced embryos at 26 hpf, 48 hpf and 72 hpf, in order to 
evaluate the cardiac shape. At 26 hpf, 60% of the morphants show defects in heart tube 
morphology, while the same occurs in 9% of the controls (Figure 24). At 48 hpf, nearly 70% of 
the morphants show impared cardiac looping or shape, while the same occurs in 8% of the 
controls (Figure 25). At 72 hpf, 41% of the morphants show heart defects in shape and / or 
looping, while the same occurs in 23% of the controls (Figure 26). 
 
 
Figure 24 
Cmlc 2 expression in silenced Cl2 (Ccdc80) embryos at 26 hpf  
A-D: cmlc 2 expression pattern analyzed by Whole-Mount in situ hybridization. Embryos at 26 hpf, injected 
with Ccdc80 morpholino (B-D), and control (A) are shown. Dorsal view, ventral is down, left is right. A: 
controls with no alterations in heart tube. B-D: morphants with alteration in heart tube, which is not properly 
oriented or shaped. 
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Figure 25 
Cmlc 2 expression in silenced Ccdc80 embryos at 48 hpf 
A-D: cmlc 2 expression pattern analyzed by Whole-Mount in situ hybridization. Embryos at 48 hpf, injected 
with Ccdc80 morpholino (B-D), and controls (A) are shown. Ventral view, head is up. A: 92 % of controls with 
no alterations. B: 33% of morphants with no alteration. C, D: 70% morphants showing enlarged atrium and / or 
impaired looping. 
 
 
 
Figure 26 
Cmlc 2 expression in silenced CL2 (Ccdc80) embryos at 72 hpf  
A-D: cmlc 2 expression pattern analyzed by Whole-Mount in situ hybridization. Embryos at 72 hpf, injected 
with Ccdc80 morpholino (B-D), and controls (A) are shown. Ventral view, head is up. A: 77% controls showing 
no alterations. B: 23% controls showing minimal cardiac alterations. C, D: 41% morphants showing cardiac 
defects in shape and/or looping.  
 
 
Amhc, was investigated in CCDC80-silenced embryos at 48 hpf. At this developing stage it is 
expressed in atrium. 21% of morphants show an enlarged atrium, while the same can be observed 
in 12.5% of the controls (Figure 27). 
 
 
Figure 27 
Amhc expression in silenced CL2 (Ccdc80) embryos at 48 hpf  
A-D: amhc expression pattern analyzed by Whole-Mount in situ hybridization. Embryos at 48 hpf, injected with 
Ccdc80 morpholino (C-D), and controls (A-B) are shown. Ventral view, head is up. A: 87.5% of controls with 
no alterations. B: 12.5% of controls showing enlarged atrium. C: 79% of morphants showing no atrial defects. C: 
21% of morphants showing enlarged atrium.  
 
 
HrT, was investigated at 26 hpf. At this developmental stage, it is expressed in the aortic root and 
in heart. No defects are detectable in the aortic expression pattern, while the cardiac expression 
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pattern is impared in 21% of the morphants. 100% of the controls show no defects in aorta and in 
the cardiac expression pattern (Figure 28). 
 
 
Figure 28 
HrT expression in silenced Ccdc80 embryos at 26 hpf  
A-H: hrT expression pattern analyzed by Whole-Mount in situ hybridization. Embryos at 26 hpf, injected with 
Ccdc80 morpholino (E-H), and controls (A-D) are shown. A, B, E, F: lateral view, anterior is left. C, D, G, H: 
Dorsal view, ventral is down, left is right. A-B: 100% controls showing no alterations in dorsal aorta. C: 84% 
controls showing no heart alterations. D: 16% of controls showing impared cardiac expression pattern. E-F: 
100% morphants showing no alterations in dorsal aorta. G: 79 % of morphants showing no heart alterations. H: 
21% of morphants showing impaired cardiac expression pattern. 
 
 
Immunohistochemistry for Ccdc80 in adult zebrafish heart appears slight positive in the 
ventricle with higher level of expression in atrium and atrio-ventricular junction (Figure 29). 
 
 
 
Figure 29  
Ccdc80 expression in zebrafish adult heart, immunohistochemistry.  
Left panel 80x, right panel 160x. 
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6.2 Expression in normal heart 
 
The expression of Ccdc80 protein in normal hearts of rats (6 samples collected) is very low 
with a patchy cytoplasmic pattern both in atria and ventricles. Focal groups of cardiomyocytes 
appear heavy stained at the atrioventricular junction (Figure 30 and 31). 
 
 
 
 
Figure 30  
Ccdc80 expression in adult rat heart, immunohistochemistry, 80x.  
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Figure 31  
Ccdc80 expression in adult rat heart (80x), immunohistochemistry. 
Panel A: atrioventricular junction; Panel B: right ventricle; 
Panel C: sepum; Panel D: left ventricle. 
 
To evaluate the expression of Ccdc80 protein in normal human hearts we performed 
immunohistochemistry on 2 hearts from healthy donors, which were not transplanted for 
logistic problems.  
Atria cardiomyocytes showed a cytoplasmic positivity with a patchy pattern: most of them 
exhibited a negative or mild staining, while only some of them showed strong positivity 
(Figure 32). 
A B 
C D 
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Figure 32  
Ccdc80 expression in adult human atria, immunohistochemistry. 
Panel A: left atrium, 80x; Panel B: right atrium, 80x 
Panel C: left atrium, 160x; Panel D: left atrium, 320x. 
 
Ventricles showed  a homogeneous moderate staining, with cytoplasmic pattern and isolated 
myocytes that appeared negative (Figure 33 and 34). 
 
A B 
D C 
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Figure 33 
Ccdc80 expression in adult human ventricles, immunohistochemistry. 
Panel A: left ventricle, 80x; Panel B: left ventricle, 160x 
Panel C and D: right ventricle, 160x. 
 
A B 
C D 
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Figure 34 
Ccdc80 protein expression in adult human ventricles.  
High-power view of myocytes, with some of them negative to immunohistochemistry. 
Panel A: left ventricle, 320x; Panel B: right ventricle, 320x; 
Panel C: left ventricle, 160x. Panel D: left ventricle 320x. 
 
Immunofluorescence analysis confirmed the cytoplasmic localization of the protein; no 
positivity was detected at nuclear level. Significant co-localization was found with sarcomeric 
proteins both in humans and rats, in particular with β-myosin, sarcomeric actin and troponin 
(Figure 35 - 37). Weaker co-localization was seen  with tropomyosin (Figure 38) and desmin 
(data not shown). 
A B 
C D 
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Figure 35 
Immunofluorescence of Ccdc80 protein, co-localization with β-myosin, rat sample. 
 
ccdc80 mergesarcomeric actin
 
Figure 36 
Immunofluorescence of Ccdc80 protein, co-localization with sarcomeric actin,  
left ventricle from human sample. 
 
Ccdc80 mergeTroponin I
 
Figure 37 
Immunofluorescence of Ccdc80 protein, co-localization with troponin I,  
left ventricle from human sample. 
 
 62 
 
 
 
Figure 38 
Merge image of immunofluorescence of Ccdc80 protein, co-localization with tropomyosin, human sample. 
 
Northern blot analysis in normal human heart showed a greater expression of the Ccdc80-
RNA in atria compared to ventricles (Figure 39). 
                              
Figure 39 
Northern Blot of Ccdc80 RNA expression.  
 
Western blot analysis confirmed the presence of the Ccdc80 protein (108 Kd) in all specimens 
(atria and ventricles) with similar expression levels. We also found an isoform of 90 kd in the 
left atrium (Figure 40). Giving that Northern blot analysis showed a greater expression of 
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Ccdc80 RNA in atria compared to ventricles, its is possible to assume that an amount of the 
protein, produced by atria, could be secreted. 
  
Figure 40 
Western Blot of Ccdc80 protein expression (graphic representation).  
 
 
 
6.3 Expression in failing heart 
Compared to normal, MC-treated rats with right ventricle hypertrophy and failure showed an 
overexpression of Ccdc80 protein. Right ventricles of the 6 analysed rats showed a clear cut 
increase in numbers and expression of positive myocytes in comparison to controls (Figure 
41). These findings appeared less evident in left ventricle and septum (Figure 42, see also 
Figure 47 and Table 1 for comparison). 
  
Figure 41  
Ccdc80 protein expression in rat with heart failure induced by MCT, right ventricle,  
immunohistochemistry. Left panel: 80x; right panel: 160x. 
 64 
  
Figure 42  
Ccdc80 protein expression in rat with heart failure induced by MCT,  
immunohistochemistry, 160x.  
Left panel: septum; right panel: left ventricle. 
 
Atria from 14 samples of human patients affected by DCM showed a homogenous increase of 
the Ccdc80 protein expression level in comparison to normal samples: almost all 
cardiomyocytes expressed the cytoplasmic protein from a moderate to strong level   intensity 
(Figure 43 and 44, see also Figure 47 and Table 1 for comparison). 
 
Figure 43 
Ccdc80 protein expression in human sample of DCM, 
immunohistochemistry, 80x.  
Left panel: left atrium; right panel: right atrium. 
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Figure 44 
Ccdc80 protein expression in human sample of DCM, 
immunohistochemistry, left atrium.  
Left panel: 160x; right panel: 320x. 
 
In ventricles less clear differences appeared when comparing normal to DCM samples: the 
pattern of positive staining remained homogeneous without  increased expression of Ccdc80 
protein. However, there was no evidence of  negative cardiomyocytes as seen in normal 
ventricles (Figure 45 and 46, see also figure 47 and Table 1 for comparison). 
  
 Figure 45 
Ccdc80 protein expression in human sample of DCM, 
immunohistochemistry, right ventricle.  
Left panel: 80x; right panel: 160x. 
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Figure 46 
Ccdc80 expression in human sample of DCM, 
immunohistochemistry, left ventricle.  
Left panel: 80x; right panel: 320x. 
 
 
 
Figure 47 
Summary of Ccdc80 protein expression in normal (upper panels) versus  
pathological samples (lower panels); immunohistochemistry. 
Panel A, D : rat right ventricle, 80x; Panel B, E: Human left atrium, 80x; 
 Panel C, F : human left ventricle, 320 x. 
 
 
We also performed western blot analysis to quantify Ccdc80 protein expression in the 
pathological tissue. The blot showed a significant overexpression of Ccdc80 protein in both 
A B C 
D E F 
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atria and ventricles with a predominant expression in ventricles (Figure 48). It is important to 
underline here that, beyond the overexpression of the main isoform of the protein (108 Kd), 
the pathological samples also expressed different isoforms of the protein (40, 65 and 90 Kd), 
compared to normal samples. These isoforms are probably the results of intracellular post-
transcriptional elaboration, such as cleavage or phosphorylation (65Kd). 
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Figure 48 
Western Blot of Ccdc80 protein in DCM. 
Panel A: different expression isoforms of the protein . MW, molecular weight; VL, left ventricle; VR, right 
ventricle; AR, right atrium; AL, left atrium. Arrows indicate 108, 65 and 40 Kd.  
The 90 Kd band coincide with marker of molecular weight.. 
Panel B: graphic representation of findings of panel A. 
Panel C: comparison of protein expression in DCM vs normal samples.  
Absolute values, expressed in arbitrary units. 
Panel D: expression levels compared to normal samples, normalized to 1. 
 
 
 
 
 
A B 
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6.4 Skeletal muscle 
 
We also performed immunohistochemistry in samples of normal skeletal muscle and in 
pathological samples from patients affected by Duchenne muscular dystrophy.  
Normal muscle showed positive cells with intense cytoplasmic positivity alternated to 
negative cells. In positive myocytes, staining is particularly strong in proximity of the 
cytoplasmic membrane (Figure 49). To rule out that this pattern could be linked to fibers 
properties, we also carried out immunohistochemistry for slow fibers (images not shown): no 
significant association between Ccdc80 positive fibers and either slow or fast myocytes  was 
found.  
  
Figure 49  
Ccdc80 protein expression in normal skeletal muscle; immunohistochemistry.  
Left panel: transverse myocyte cut , 80x; right panel: longitudinal myocyte cut, 80x. 
 
 
Immunofluorescence analysis on normal sample confirmed the cytoplasmic localization of the 
protein, particularly in proximity of the cytoplasmic membrane (Figure 50). 
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Figure 50  
Ccdc80 protein expression in normal skeletal muscle; immunofluorescence.   
 
 
The pathological skeletal muscles showed almost all myocytes expressing the protein with a 
moderate to strong positivity (Figure 51). 
 
Figure 51 
Ccdc80 protein  expression in pathological skeletal muscle (Duchenne muscular dystrophy); 
immunohistochemistry; left panel: transverse myocyte cut, 20 x; right panel longitudinal myocyte cut, 40x. 
 
 
 
 
 
 
 
 70 
Sample Normal pattern N Pathological pattern N 
Rat atria Negative staining, few 
myocytes with 
moderate/strong positivity 
6 NA  
Rat right 
ventricle 
Negative staining, few 
myocytes with 
moderate/strong positivity 
6 Patchy, mild/moderate 
staining, few groups of 
myocytes with strong 
positivity 
6 
Rat septum and 
left ventricle 
Negative staining, few 
myocytes with 
moderate/strong positivity 
6 Patchy, mild/moderate 
staining, few groups of 
myocytes with strong 
positivity 
6 
Human atria Patchy, negative or mild 
staining, few groups of 
myocytes with strong 
positivity 
2 Homogeneous, moderate to 
strong staining 
14 
Human 
ventricles 
Homogeneous moderate 
staining, isolated myocytes 
negative 
2 Homogeneous moderate 
staining, no evidence of 
isolated negative myocytes  
14 
Human skeletal 
muscle 
Positive myocytes with 
moderate/strong staining 
alternated to negative ones 
2 Almost all myocytes with a 
moderate to strong staining 
2 
Table 1 
Summary of Ccdc80 protein  immunohistochemical expression 
 in normal versus pathological samples. 
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7. Discussion  
Zebrafish heart is the first organ to form and function during embryonic development [126]. 
The cardiac field is located within the lateral plate mesoderm and is specified in the 
segmentation period. In early somitogenesis the cardiac precursors converge in the embryonic 
midline and are recognizable for the expression of the abovementioned transcription factor 
nkx2.5 [122]. Endocardium and myocardium, with the specification of atrial and ventricular 
cell populations, are soon defined, and at 24 hpf the heart tube assembly is completed and 
shows regular contractions (Figure 52). Within the same developing stage, also axial vessels 
complete and, just after that, trunk circulation begins. At 48 hpf cardiac looping is completed 
and the formation of the cushions at the atrio-ventricular junction starts. These cushions will 
later differentiate into the atrio-ventricular valve.  
 
Figure 52  
Zebrafish heart development  
a | Just before gastrulation, 5 h post fertilization (hpf), the heart progenitor cells are located throughout the 
ventral and lateral regions of the embryo. b | After involution, these cells converge towards the embryonic axis 
and reach their destination at the level of the future hindbrain by the five-somite stage (~12 hpf). Three rows of 
cells are represented at this stage, the endocardial precursors (blue) lie most medially and the myocardial 
precursors most laterally. c | By the 13-somite stage (15.5 hpf), the myocardial precursors have segregated into 
preventricular (red) and preatrial (yellow) groups, although this segregation might well happen earlier. d | 
Starting at 19 hpf, the myocardial precursors merge posteriorly to form a horseshoe-shaped structure. By 19.5 
hpf, as anterior cells migrate medially, the horseshoe transforms into a cone with the ventricular cells (red) at its 
centre and apex, and the atrial cells (yellow) at its base. The endocardial cells (blue) line the inside of the cone. e 
| Next, the cone telescopes out to form a tube. The ventricular end of the heart tube assembles first, followed by 
the atrial end. f | By 24 hpf, the tube lies along the anteroposterior axis with the atrial end to the left of the 
midline. Subsequently, by 30 hpf, visibly distinct ventricular and atrial chambers form. g | By 36 hpf, the heart 
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undergoes looping morphogenesis. and, by 48 hpf, functional valves are formed. (A, anterior; AP, animal pole; 
D, dorsal; P, posterior; V, ventral; VP, vegetal pole; L, left; R, right.).  
 
 
In zebrafish, our findings showed that Ccdc80 protein is expressed in the forming heart, 
during all the developmental stages, and in particular in the atrio-ventricular boundary, in 
bulbus arteriosus and in the aortic arch at 48 hpf.  
We also showed that Ccdc80-morphants showed defects in the developing heart, with a 
general enlargement of the atrium and impaired cardiac looping or shape, starting from the 
hatching period, at 48 hpf; moreover, at 72 hpf, the morphants showed more severe cardiac 
defects with blood stasis, evident in the sinus venosus region and peripheral congestion such 
as in heart failure; in addition they showed severe diffuse oedema, also in pericardial cavity 
and in the cranial cavity. It is important to underline that the defects in the heart of zebrafish 
morfants became evident only after pharyngula period of development (24-26 hpf): thus the 
phenotypical alterations were due to a disorder of the late phase of cardiac development, after 
the complete differentiation of myocytes. 
Impaired cardiac looping and similar phenotypical alterations can be also produced by 
silencing of other genes, like bone morphogenetic protein (bmp)4, fibroblast growth factor 
(FGF) and notch1b, as well modifying wnt/β-catenin pathway, that are involved in atrio-
ventricular junction development [127-131]. In particular, in zebrafish notch1b and bmp4 are 
initially expressed throughout the anterior-posterior part of the heart and, subsequently, the 
expression of these genes is restricted to the area of the valve in formation (bmp4 in the 
myocardium and notch1b in the endocardium). About 48 hpf, there is the higher expression of 
notch1b and bmp4 respectively in the endocardium and myocardium of the atrio-ventricular 
junction (Figure 53) [131]. 
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Figure 53  
Notch1b and bpm4 expression in zebrafish heart at 48 hpf. 
Localization of notch1b and bmp4 in the heart of zebrafish. A: expression of notch1b endocardium highlighted 
by in situ hybridization. B: Schematic representation of the expression pattern of notch1b.  
C: bmp4 expression in the myocardium as evidenced by in situ hybridization.  
D: schematic representation of the expression pattern of bmp4. 
 
 
In summary, we demonstred that Ccdc80 protein is indispensable for correct heart 
development in zebrafish model and that the phenotypical alterations are due to a disorder of 
the late phase of cardiac development, after the complete differentiation of myocytes. Giving 
the known interactions of Ccdc80 protein with intracellular pathways, in particular with 
wnt/β-catenin and bpm4, and giving the similar phenotypical alterations, is likely that Ccdc80 
plays a similar key role in heart developing and morphology [91, 132]. 
Moreover, data obtained from immunohistochemistry showed that Ccdc80 protein exhibit a 
different pattern of expression in pathological conditions compared to normal hearts. 
The atria of human patients affected by DCM showed a homogenous increase of the Ccdc80 
expression level (moderate to strong staining) in comparison to normal samples (patchy 
pattern with negative or mild stain and only a few groups showing strong positivity).  
In ventricles there is no evidence of spread negative cardiomyocytes, although the pattern 
remains homogeneous without evident increased expression of Ccdc80 protein. 
Ventricles of MCT rats, compared to normal ones, also showed a clean-cut over-expression of 
Ccdc80 protein, particularly at right ventricular level, probably due to the higher pressure 
overload. Furthermore, skeletal muscle showed a similar modification of the pattern in 
pathological condition, with almost all myocytes expressing the protein with a moderate to 
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strong positivity. This pattern appeared very different from normal muscle, which show 
positive cells with intense positivity alternated to negative cells. 
The western blot confirmed a significant over-expression of Ccdc80 protein in both atria and 
ventricles of DCM samples, with a 5-12 fold increased expression compared to normal 
samples. Among four different bands of Ccdc80 isoforms, normal samples express only the 
108Kd form while DCM samples also showed different isoforms of the protein. Two of them 
were recognized as cleaved and phosphorylated isoform of 65Kd (SSG1) and as a probably 
secreted isoform, of 40Kd. Moreover, giving that in normal samples Northern blot analysis 
showed a greater expression of Ccdc80 RNA in atria compared to ventricles, its is possible to 
assume that an amount of the protein, produced by atria, could be secreted. 
Taken together, these results suggest a possible role of Ccdc80 as a protein with an adaptive 
function, that is overexpressed in stress conditions, such as  pressure/volume overload and 
myocytes dysfunction. It is well known indeed that Ccdc80 is up-regulated in stress related 
cardiac hypertophy [110, 133]. 
Moreover, cultured muscle cells display reductive metabolic and muscle-system 
transcriptome adaptations, with particular increased expression of Ccdc80, as observed in 
muscle atrophy, activating tissue-remodeling and senescence processes [104]. This confirms a 
potential key role of Ccdc80 in stress related metabolic and intracellular adaptation. 
Under pathological stress, the heart reactivates several signaling pathways that traditionally 
were thought to be operational only in the developing heart. One of these pathways is the 
WNT signaling pathway: Wnt controls heart development but is also modulated during adult 
heart remodelling and the interaction of Ccdc80 with this pathway is also well defined. 
Besides wnt/β-catenin pathway, also PKI-GMP dependent is constitutively expressed in adult 
heart with an important role. 
In particular PKGI and cGMP inhibit left ventricular remodeling in response to pressure 
overload [108-109], and left ventricular pressure overload itself is known to modulate cardiac 
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SSG1 (orthologous of Ccdc80) expression [110]. The elevation of myocyte cyclic GMP levels 
by local actions of endogenous atrial natriuretic peptide (ANP) or by pharmacological 
inhibition of phosphodiesterase-5 was shown to counter-regulate pathological hypertrophy. 
Otherwise loss of cGKI in cardiac myocytes compromises the hypertrophic program to 
pathological stimulation, rendering the heart more susceptible to dysfunction [134]. 
Moreover, the overexpression of cGMP-dependent protein kinase type 1a (PKG1a) has been 
demonstrated to improve mesenchymal stem cells contributing to regeneration of the ischemic 
heart after myocardial infarction [135]. In addition, cGMP was shown to inactivates 
glycogensynthase kinase 3β (GSK-3β) via PKG by preventing the mitochondrial permeability 
transition pore (mPTP) opening. This leads to acute cardioprotection but also lead to 
prevention of hypertrophy and heart failure, by negatively regulating Akt activity (which, 
besides to critical for acute cardioprotection, can also lead to cardiac hypertrophy in case of 
excessive activation) [136]. Therefore, cGMP is a versatile signal with dual beneficial role in 
cardiac cell survival and Ccdc80 (in particular its ortologue SSG1), as PKGI phosphorylated 
substrate, could also protect myocardium from both hypertrophy and ischemia/reperfusion 
injury. Furthermore, Wnt inhibitors, which include also Ccdc80, could enhance the efficiency 
of BMP-4-directed cardiac differentiation of human pluripotent stem cells [137]. 
In experimental settings [138] frizzled-related proteins (sFRPs) can block Wnt activation 
signaling and sFRPs injected into the heart attenuated LV remodelling; depletion of a 
disheveled isoform (a signalling intermediate of both the canonical and noncanonical WNT 
pathway) attenuated LV remodelling while disheveled activation led to progressive dilated 
cardiomyopathy. Inhibition of nuclear β-catenin signaling downstream of the canonical WNT 
pathway significantly reduced postinfarct mortality and functional decline of LV function 
following chronic left anterior descending coronary artery ligation.  
In summary, Wnt pathway plays a pivotal role in adult cardiac remodeling and may be 
suitable for therapeutic interventions (Figure 54). Currently, several molecular and cellular 
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mechanisms whereby WNT inhibition attenuates LV remodeling are proposed.  
 
Figure 54  
Schematic summary of cellular mechanisms contributing to the observed attenuation of  
LV remodeling on inhibition of WNT signaling at different levels. 
 
 
Giving that Ccdc80 seems to have different roles in developing heart and in adult heart, 
likewise to other intracellular pathways, future studies will focus on two different directions. 
In particular, will be important to analyze the mutual relationship between Ccdc80 and 
notch1b, bmp4 and wnt pathway, with the aim to define their roles in the process of heart 
development, expecially of the atrioventricular junction. Moreover, to clarify the functional 
role of Ccdc80 during heart failure and disease, future studies should examinate specific 
models of zebrafish heart failure, with or without knocking down Ccdc80; similarly, could be 
interesting to analyze the response of Ccdc80 KO rats to monocrotaline infusion. In addition, 
further investigation are needed to explore the function of Ccdc80 and its relationship with 
other intracellular networks, both under normal conditions and during disease. 
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8. Conclusions 
We demonstrated that Ccdc80 is expressed in the forming heart in zebrafish, during all the 
developmental stages, and that it is necessary for correct heart development. Ccdc80-
morphants, indeed, showed defects in the developing heart, with impaired cardiac looping, 
atrium enlargement, blood stasis and peripheral congestion. These phenotypical alterations, 
which represent a proper heart failure, are due to a disorder of the late phase of cardiac 
development, after complete myocyte differentiation. 
In normal human and rats, Ccdc80 mRNA, analized by Northern blot technique,  showed a 
higher expression in atria compared to ventricles, while the Ccdc80 protein (108 Kd), analized 
by Western blot, showed similar expression levels in atria and ventricles. Ccdc80 protein 
showed a cytoplasmic localization with evident co-localization with sarcomeric proteins. 
By immunohistochemistry, MCT rats, compared to normal ones, showed evident overexpression 
of Ccd80 protein especially in right ventricles, probably due to higher pressure overload. Also 
human atria of DCM patients showed evident overexpression of Ccdc80 with an homogenization 
of the expression pattern, compared to normal samples. Similar results are shown in stressed 
skeletal muscles. Although, there was no more evidence of  spread negative cardiomyocytes in 
pathological heart, less clear difference are evident between normal and pathological 
ventricles. Interestingly, in western blot, beside a significant overexpression of Ccdc80 in 
both atria and ventricles, the pathological samples expressed different isoforms of the protein 
(40, 65 and 90 Kd) in comparison to normal samples, probably due to intracellular post-
transcriptional processing of the protein. 
In conclusion, our results demonstrated that Ccdc80 played a fundamental role for correct 
heart development and, in formed heart, shows a likely role as an adaptive protein to stress 
conditions such as pressure overload and myocytes dysfunction.   
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